Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?

Mark Sweeney¹,², Ben Corden¹,³,⁴,⁵ & Stuart A Cook¹,³,⁴,⁵,*

Abstract

Cardiac fibrosis is central to the pathology of heart failure, particularly heart failure with preserved ejection fraction (HFrEF). Irrespective of the underlying profibrotic condition (e.g. ageing, diabetes, hypertension), maladaptive cardiac fibrosis is defined by the transformation of resident fibroblasts to matrix-secreting myofibroblasts. Numerous profibrotic factors have been identified at the molecular level (e.g. TGFβ, IL11, AngII), which activate gene expression programs for myofibroblast activation. A number of existing HF therapies indirectly target fibrotic pathways; however, despite multiple clinical trials in HFrEF, a specific clinically effective antifibrotic therapy remains elusive. Therapeutic inhibition of TGFβ, the master-regulator of fibrosis, has unfortunately proven toxic and ineffective in clinical trials to date, and new approaches are needed. In this review, we discuss the pathophysiology and clinical implications of interstitial fibrosis in HFrEF. We provide an overview of trials targeting fibrosis in HFrEF to date and discuss the promise of potential new therapeutic approaches and targets in the context of underlying molecular mechanisms.

Keywords CMR; fibroblast; fibrosis; heart failure; HFrEF

Introduction

Heart failure (HF) is a major public health problem with an estimated worldwide prevalence of over 23 million (Bui et al., 2011; Ponikowski et al., 2014)—a figure projected to rise as populations age (Conrad et al., 2018). Despite advances in the treatment of HF over the last decades, mortality and morbidity remain high and HF is a major contributor to the global health economic burden (Lesyk et al., 2018). It is increasingly clear that cardiac fibrosis plays a role in the aetiology of all forms of HF and in particular the pathophysiology of HF with preserved ejection fraction (HFrEF) (Moreo et al., 2009; González et al., 2018).

Fibrosis is an evolutionarily conserved physiological process intended to repair, replace and reinforce severely or chronically injured tissue when tissue regenerative and homeostatic mechanisms are exhausted. Fibrosis ultimately results in the accumulation of extracellular matrix (ECM) at the site of injury and the production of a “scar”. Short-term fibrotic processes can be adaptive, but persistent activation of fibrotic pathways, as occur in HFrEF, results in excess accumulation of ECM and disruption of tissue function (Rockey et al., 2015). Much research has been carried out in the field of cardiovascular fibrosis, identifying potential antifibrotic targets that may provide new strategies to treat HF. In this review, we summarize the processes involved in the development of HFrEF focussing on interstitial cardiac fibrosis and its contribution to HF, discuss strategies which have been implemented to date—with limited success—and highlight the new opportunities.

HFrEF

The classical definition of HF is “an inability of the heart to pump blood to the body at a rate commensurate with its needs, or to do so only at the cost of high filling pressures” (Braunwald, 1988) which presents clinically as a syndrome of exertional breathlessness, peripheral oedema and fatigue. HF can be further categorized as HFrEF with reduced ejection fraction (HFrEF) or HFrEF (Ponikowski et al., 2016). In HFrEF, the systolic force generation of the heart is impaired, and consequently, the proportion of blood expelled with each contraction—the ejection fraction—is reduced. In HFrEF, routine parameters of systolic function are largely maintained but diastolic filling and relaxation are impaired (Ponikowski et al., 2016).

While several therapies exist for HFrEF—including beta-blockers, drugs targeting the renin–angiotensin–aldosterone system (RAAS) and sodium-glucose co-transporter 2 (SGLT2) inhibitors—no treatment has yet been shown to be effective for HFrEF despite multiple...
Glossary

Cardiac fibroblast
Cells resident within the myocardium which express mesenchymal markers and secrete ECM proteins.

Diabetic nephropathy
Kidney disease caused by the effects of hyperglycaemia on the structure and function of the glomerulus.

Dilated cardiomyopathy
Heart muscle disease, often with a genetic component, characterized by progressive dilation and dysfunction of the cardiac chambers leading to heart failure.

Extracellular matrix
A complex network of interconnected structural proteins, glycoproteins and enzymes which reside in the extracellular space and provide structural and biochemical support to surrounding cells.

Extracellular volume
Magnetic resonance imaging measurement technique which allows the quantification of diffuse collagen deposition within a tissue.

Fibrosis
The accumulation of excess extracellular matrix proteins within the extracellular space distorting the architecture and the function of the native tissue.

Heart failure with preserved ejection fraction
Clinical syndrome of heart failure where, although the routinely measured parameters of systolic function are normal, dysfunction of relaxation and passive filling results in heart failure symptoms.

Heart failure with reduced ejection fraction
Clinical syndrome of heart failure where the contractile force is reduced and the proportion of blood expelled with each contraction is below the normal range.

Heart failure
A syndrome of clinical signs and symptoms characterized by the inability of the heart to provide sufficient cardiac output to match the physiological demands of the body.

Hypertensive heart disease
Changes within the heart in response to chronic hypertension which includes cardiomyocyte hypertrophy and fibrosis which can result in heart failure.

Hypertrophic cardiomyopathy
A heart muscle condition, often inherited, resulting in ventricular hypertrophy in the absence of abnormal loading conditions.

Interstitial fibrosis
The accumulation of ECM in the absence of large-scale cell death in the interstitial and perivascular spaces.

Myocardial infarction
Myocardial damage caused by insufficient blood supply to a myocardial region leading to cell death and fibrotic scar formation.

Myofibroblast
Activated fibroblasts with a highly secretory and contractile phenotype which are responsible for the majority of ECM production in pathological states.

Oxidative stress
An imbalance between the production of reactive oxygen species within a tissue and its ability to clear these with antioxidants.

Replacement fibrosis
The deposition of ECM to replace dead or damaged cells and preserve the structural integrity of a tissue.

Transverse aortic constriction
An experimental surgical animal model of pressure overload involving creation of a stenosis in the transverse aorta causing increased pressure in the left ventricular cavity, resulting in hypertrophy, fibrosis and—ultimately—heart failure.

Ventricular remodelling
The changes that occur within the ventricular myocardium in response to pressure or volume overload leading to cardiomyocyte hypertrophy and accumulation of fibrotic tissue.

randomized trials (Ponikowski et al., 2016; Pfeffer et al., 2019; Seferovic et al., 2019). This is of particular concern as HFP EF is common—estimated to be responsible for > 50% of HF cases (Vasan et al., 2018)—and is growing increasingly more so due to its association with ageing and comorbidities such as diabetes, renal dysfunction, hypertension, non-alcoholic fatty liver disease and sarcopenia (Bekfani et al., 2016; Dunlay et al., 2017; Streng et al., 2018).

Echocardiographic and invasive haemodynamic measurements in HFP EF have described impairment in both diastolic function (Kasner et al., 2011; Hummel et al., 2017) and in non-classical measures of systolic function, such as longitudinal contraction (Kraigher-Krainer et al., 2014). Characteristic changes in diastolic function include impairment of ventricular relaxation (Zile et al., 2004) resulting in reduced ventricular compliance and reduced efficiency of ventricular filling during diastole (Hay et al., 2005; Westermann et al., 2008). Maintenance of adequate stroke volume in this setting necessitates elevation of ventricular filling pressures particularly during exercise when diastolic filling time is limited (Westermann et al., 2008). Neurohormonal systems including the sympathetic and RAAS are activated which promote salt and water retention in the kidney. Over time, the increased circulating volume and high levels of AngII and aldosterone are maladaptive, increasing ventricular stretch, oncostatic pressure in the lungs and peripheries and exerting a potent prohypertrophic and profibrotic effect within the myocardium (Diez, 2004; Brown, 2013).

HFP EF does not represent a single pathological process but is a complex disease, with many contributing pathophysiological mechanisms (Cohen et al., 2020) both within the cardiomyocyte, in the surrounding tissue (Fig 1) and in peripheral tissues (not discussed here). Endothelial dysfunction has repeatedly been associated with development of HFP EF and is predictive of diastolic dysfunction and subsequent HFP EF in asymptomatic patients (Yang et al., 2020). Healthy endothelium releases nitric oxide (NO) which is a key homeostatic mediator with effects on vascular smooth muscle cells, cardiomyocytes and fibroblasts and has been suggested to be a cornerstone of HFP EF pathophysiology (Paulus & Tschöpe, 2013). Cardiomyocyte hypertrophy (Takimoto et al., 2005), increased myocardial stiffness (Bishu et al., 2011) and cardiac fibrosis (Calderone et al., 1998) have all been associated with reduced NO signalling through decreased cyclic GMP production and inhibition of protein kinase G activity in various cell types (Paulus & Tschöpe, 2013).

Dysfunctional endothelial cells also express high levels of vascular adhesion molecules which promote the migration of inflammatory cells into the myocardium (Westermann et al., 2011). Inflammatory cell infiltration is augmented by local release of inflammatory mediators including IL-1, IL-6 and TNF-a in response
to hypoxia or local tissue damage (Turner et al., 2007; Yu et al., 2012). Systemic inflammatory conditions including rheumatological conditions, diabetes or metabolic syndrome which are associated with HFpEF prime immune cells to initiate exaggerated inflammatory and fibrotic responses when recruited to tissues (Esposito et al., 2002; Umare et al., 2014). Inflammation within the myocardium increases oxidative stress, reduces cGMP production, damages the endothelium and impairs cardiomyocyte performance (Picchi et al., 2006; Waddingham et al., 2019). If persistent, inflammation can be associated with the emergence of profibrotic macrophages (Westermann et al., 2011; Peet et al., 2019) and infiltration of Th1 T cells (Nevers et al., 2017). These inflammatory cells express transforming growth factor β (TGFβ), interferon-γ, Galectin-3 (Gal-3), connective tissue growth factor and angiotensin-converting enzymes which activate cardiac fibroblasts (CF) thereby promoting the deposition of ECM and the occurrence of fibrosis.

At the level of cardiomyocytes, mechanical stretch, neurohormonal activation and oxidative stress lead to a hypertrophic response with increased sarcomere numbers, cardiomyocyte area, myocardial mass and impaired relaxation kinetics (Kojima et al.,...
Fibrotic changes in the heart can be broadly categorized into distinct types, with fibrosis histology playing a crucial role. Increased symptoms (Kasner et al., 2011; Krüger et al., 2009). Oxidative stress within the heart is elevated in HFpEF (Vitiello et al., 2014) particularly in conditions such as obesity, hypertension and diabetes which can cause mitochondrial dysfunction (Sverdlov et al., 2016; Sorop et al., 2018), uncouple the electron transport chain (Boudina et al., 2007), upregulate reactive oxygen species (ROS)-producing enzymes (Ide et al., 2000; Moris et al., 2017) and reduce antioxidant activity (Ballal et al., 2010). Oxidative stress impacts NO signalling, the phosphorylation state of sarcomeric proteins, calcium handling and hypertrophy within the cardiomyocyte. This results in increased myocardial stiffness, impaired energetic metabolism and a profibrotic, pro-inflammatory secretome which contributes to and perpetuates the haemodynamic changes of HFpEF.

**Fibrosis in HFpEF**

Among the multiple factors contributing to the development of HFpEF, fibrosis is a common pathway which exists regardless of aetiology. In patients with symptomatic HFpEF, extracellular fibrotic burden is more strongly correlated with diastolic dysfunction than is cardiomyocyte stiffness (Zile et al., 2015) and fibrosis is correlated with increased arrhythmias (Cho et al., 2018) hospitalization and mortality in HFpEF (Kanagala et al., 2019) making it an attractive therapeutic target. There is a prolonged asymptomatic phase prior to the development of HFpEF in which significant structural and haemodynamic changes accumulate within the heart but without limiting symptoms (Abhayaratna et al., 2006; Kosmala & Marwick, 2020). Although reducing cardiomyocyte stiffness, endothelial dysfunction and oxidative stress may provide beneficial effects in the early stages of disease, reversing fibrotic changes and positively remodelling the myocardium is crucial to improve cardiac function and ameliorate symptoms late in the disease as symptoms are beginning to develop (Kim et al., 2018).

Fibrotic tissue is predominantly composed of fibrillar collagens such as collagen I and collagen III which strongly influence the biomechanical properties of the ECM. Fibrillar collagens have high tensile strength providing structural support to the myocardium, however when present in excess, reduces myocardial compliance (de Souza, 2002). Collagen subtypes have differing elastic properties, and therefore, the ratio between collagen subtypes in addition to increased quantity is important for the physiological effects seen in the fibrotic heart. Collagen I accounts for 85–90% of collagen within the healthy heart with collagen III making up 5–10% and smaller contributions from other collagen subtypes (Weber, 1989; de Souza, 2002). Collagen I is less compliant when exposed to tension compared to collagen III which has more elastic properties (Collier et al., 2012; Asgari et al., 2017). An increased ratio of type I vs. type III collagens is seen in both animal and human models of pressure overload (Kasner et al., 2011; López et al., 2014; Echegaray et al., 2017) and is correlated with worsening diastolic function and increased symptoms (Kasner et al., 2011).

**Fibrosis histology**

Fibrotic changes in the heart can be broadly categorized into distinct but not mutually exclusive categories of (i) replacement or (ii) reactive/interstitial fibrosis (Fig 2). Replacement fibrosis is classically associated with myocardial infarction (MI) where cardiomyocyte cell death and muscle loss are replaced by ECM proteins to maintain the structural integrity of the heart wall. This is a crucial process to reinforce areas of the myocardium weakened by cardiomyocyte loss and prevent myocardial rupture. The resulting area of fibrotic scar is non-contractile, non-elastic tissue that does not contribute to force generation. Thus the size, composition and physical properties of the fibrotic scar have major implications for the development of HF.

So-called “reactive fibrosis” is an alternative form of cardiac fibrosis which occurs in the absence of large-scale cardiomyocyte death and will be the focus of the remainder of this review. There are two major histologically distinct forms of reactive fibrosis—interstitial and perivascular—which often coexist. Interstitial fibrosis involves the deposition of collagen-rich ECM in the interstitial space between cells and is most commonly associated with chronic stressors that include abnormal loading conditions (e.g. hypertension, post-MI or valve pathology) (Brilla et al., 2000; Treibel et al., 2018b) or profibrotic systemic conditions (Shimizu et al., 1993; Eschaller et al., 2014; Kobayashi et al., 2017). Perivascular fibrotic tissue is rich in inflammatory cell infiltrate and is more prominent in conditions where endothelial damage predominates such as hypertensive heart disease (HHD) or diabetes (Hinglais et al., 1994; López et al., 2006). ECM production in perivascular fibrosis may have a greater role for endothelial to mesenchymal transition (Endo-MT; a debated process) (Zeisberg et al., 2007; Okayama et al., 2012), fibroblastic differentiation of pericytes (Kramann et al., 2015) and infiltration of inflammatory cells (Hinglais et al., 1994; Hara et al., 2002; Nevers et al., 2017). Perivascular fibrosis is also associated with abnormalities in coronary blood flow (Dai et al., 2012), and increased diffusion distance from the endothelium to cardiomyocytes reduces the diffusion of oxygen, fatty acids, glucose and signalling molecules such as NO (Nevers et al., 2017). However, differentiating the effects of interstitial and perivascular fibrosis is challenging as these processes typically coexist and for technical reasons are normally grouped together in analysis.

In human disease, myocardial interstitial fibrosis typically builds up over many years before manifesting clinically, leading to the important question of its reversibility. Fortunately, fibrosis does not exist as an inert, metabolically inactive tissue but rather undergoes continual remodelling controlled by the activity of fibroblasts, immune cells and proteolytic enzymes. The removal of pressure overload in animal studies results in positive myocardial remodelling with reduced interstitial collagen (Walther et al., 2001; Szardien et al., 2012). Similarly, human studies in patients with aortic stenosis have demonstrated a gradual reduction in interstitial cardiac fibrosis following aortic valve replacement (Villari et al., 1995; Treibel et al., 2018b). This positive remodelling has also been replicated using RAAS pathway inhibitors in hypertensive heart disease with associated improvement in cardiac haemodynamics (Brilla et al., 2000; Diez et al., 2002). Replacement fibrosis, unlike diffuse fibrosis, was not shown to resolve following treatment of aortic stenosis (Treibel et al., 2018b) which may be partly explained by increased collagen cross-linking within areas of replacement fibrosis which render the tissue resistant to collagenase mediated degradation (Frangogiannis, 2019). Interstitial fibrosis tends to be less heavily cross-linked than replacement fibrosis but increased...
cross-linking of interstitial fibrosis is associated with diabetes (Liu et al., 2003) and hypertension (Norton et al., 1997; Badenhorst et al., 2003; López et al., 2016). High levels of collagen cross-linking have been suggested as an explanation for lack of efficacy in trials of anti-fibrotics in HFpEF (Ravassa et al., 2018). Therefore, early identification and treatment of patients with HFpEF and cardiac fibrosis may be important for achieving optimal outcomes.

**Monitoring of cardiac fibrosis in clinic**

Given the heterogeneous pathophysiology of HFpEF, the ability to detect and monitor changes in fibrosis over time is optimal for identifying patients most likely to benefit from antifibrotic interventions and define the effectiveness of these treatments in clinical trials. The gold standard measure of cardiac fibrosis is histological analysis of endomyocardial biopsy (EMB) samples stained for collagen using...
Surrogate markers have been developed to non-invasively quantify myocardial fibrosis and overcome some of the limitations of EMB. During ECM synthesis, collagen is released as a promolecule requiring cleavage of the amino and carboxyl-terminals by collagen peptidase to form mature collagen fibrils. These cleaved terminal peptides can be measured in serum to give an indication of the quantity of collagen formation. To date, the carboxyl-terminal of procollagen I (PICP) has shown the most promise in HFpEF. PICP is associated with raised collagen content on EMB, diastolic dysfunction and prognosis in HFpEF (Querejeta et al, 2000; López et al, 2015a,b). Alternative markers of collagen synthesis including the amino-terminal of procollagen I (PINP) and III (PIIINP) have been detected in serum and are elevated in hypertensive patients (Díez et al, 1995) and those with hypertrophic cardiomyopathy (HCM) (Lombardi et al, 2003). However PINP and PIIINP have not been convincingly associated with histological measures of cardiac collagen in HFpEF (López et al, 2015a,b). Similarly, the C-terminal telopeptide produced during the degradation of collagen I (CITP) can be measured in serum to provide a surrogate measure of collagen degradation which has shown an association with HFpEF symptoms (Martos et al, 2009). However, the extent to which these biomarkers, when measured peripherally, are representative of changes in myocardial collagen content is unclear. Studies sampling directly from the coronary sinus (CS) have yielded conflicting results regarding the cardiac contribution to the circulating levels of terminal peptides. PICP is elevated in CS samples from HHD patients (Querejeta et al, 2004); however, CS measurement of PINP, PIIINP and CITP do not show association with the burden of fibrosis measured by histology or cardiac magnetic resonance imaging (CMR) (Kupari et al, 2013; Nagao et al, 2018). Peripheral measurements of collagen biomarkers are more likely to represent a systemic profibrotic or inflammatory state than to specifically reflect the level of cardiac fibrosis. In spite of this, given the multisystemic nature of HFpEF, this does not preclude these markers from having role in prognosticating disease or guiding therapy (Krum et al, 2011) but caution must be exercised when drawing conclusions about cardiac collagen content from use of these biomarkers, and currently, they remain a research tool.

Advances in CMR have made the non-invasive quantification and localization of fibrosis within the myocardium possible, and CMR compares favourably with histological measures (Diao et al, 2016). CMR has many potential advantages compared to invasive histology based assessment; sampling errors seen with EMB are reduced as the entire myocardium is imaged, CMR is non-invasive and low risk allowing serial scans in the same patient to track progression or resolution of fibrosis over time, and structural and functional information can be collected as part of the same study.

Late gadolinium contrast enhancement (LGE) imaging has been used extensively to identify focal areas where volume of distribution is increased and contrast washout delayed which correlates with fibrotic areas histologically (Schelbert et al, 2010). Although LGE is primarily detects areas of replacement fibrosis, this still correlates with cardiac function in HFpEF across aetiologies including HHD (Rudolph et al, 2009; Krittayaphong et al, 2010), aortic stenosis (Nigri et al, 2009; Everett et al, 2020), diabetic cardiomyopathy (Kwong et al, 2008) and HCM (Bruder et al, 2010; Moravsky et al, 2013).

More recently, CMR measurement of the interstitial component of cardiac fibrosis has become possible due to the advent of T1 mapping (Löffler et al, 2019). T1 mapping uses precontrast and post-contrast magnetic resonance measurements from the myocardium to provide a quantitative assessment of the extracellular volume (ECV) within an area of myocardium. ECV is highly correlated with collagen content measured histologically (Diao et al, 2016; Duca et al, 2016), functional measures of diastolic function (Rommel et al, 2016) and prognosis in HFpEF (Mascherbauer et al, 2013; Schelbert et al, 2017). Clinical trials of antifibrotic HFpEF therapies are starting to use CMR-derived ECV measures in patient selection and as an outcome measure (Lewis et al, 2019). This may begin to address some of the long-standing issues with patient selection for HFpEF clinical trials (Kelly et al, 2015) ensuring these therapies are targeted at the group of patients most likely to benefit.

**Cellular and molecular mechanisms of fibrosis**

**Myofibroblasts—the cellular driver of fibrosis**

A central event in the development of fibrotic changes within the heart is the accumulation of activated myofibroblasts at the site of injury (Moore-Morris et al, 2014; Rockey et al, 2015; Kanisicak et al, 2016). Myofibroblasts exhibit two cardinal features: firstly, they secrete large amounts of ECM components, and secondly, via the expression of smooth muscle actin (SMA, otherwise known as ACTA2), they are contractile (Wynn, 2008; Rosenbloom et al, 2017). Together, these features result in the expansion of ECM, increased tissue stiffness and ventricular remodelling typical of cardiac fibrosis and HF.

The cellular origin of myofibroblasts in vivo has been debated extensively (Di Carlo & Peduto, 2018) with multiple candidates having been identified in the literature including epicardial or endothelial cells undergoing mesenchymal transition or migration of hematopoietic cells or pericytes into the interstitium (van Amerogen et al, 2008; Krenning et al, 2010; Widjantoro et al, 2010). Lineage tracking studies of myofibroblasts using peristin as a marker of myofibroblast activation have found that resident cardiac fibroblasts (CF) in the myocardium are the most significant contributor to the myofibroblasts population in cardiac injury with minimal input from extracardiac sources or endothelial structures (Acharya et al, 2012; Moore-Morris et al, 2014; Kanisicak et al, 2016).

Recent cell sorting experiments suggest that resident CF make up approximately 10% of the total cell number within the heart which is significantly less than previous estimates when fibroblasts were considered to be the most abundant cell within the heart (Banerjee et al, 2007; Pinto et al, 2016; Tallquist & Molkentin, 2017). This lack of consensus on the origin, definition and relative proportion of ECM-producing cells within the heart is in part due to the extensive heterogeneity among this cell type. Significant variation in synthetic
function, morphology and gene expression exists among CF depending upon their origin, anatomical site within the heart and state of activation. A variety of cell surface and intracellular markers has been used to identify these cells including fibroblast-specific protein (FSP1), DDR2, Sca-1, Thy-1, fibronectin and vimentin (Hudon-David et al., 2007; Ivey & Tallquist, 2016). However, no single marker is sufficiently comprehensive or specific (Kong et al., 2013), and as a result, combinations of cell markers have been used to define CF, although likely incompletely.

Two markers which appear to be relatively more specific to CF are the platelet-derived growth factor receptor α (PDGFRα) and the transcription factor Tcf21, both of which are expressed in the majority of myofibroblast-forming cells (Smith et al., 2011; Acharya et al., 2012; Pinto et al., 2016). PDGFRα and Tcf21 are both expressed in the epicardial layer of the developing heart and are necessary for epithelial to mesenchymal transition of epicardial cells. Genetic knockout of Tcf21 leads to a paucity of CF within myocardium, and lineage tracking studies suggest an epicardial origin for a majority of resident CF (Smith et al., 2011; Acharya et al., 2012). An endothelial origin has been identified for a smaller proportion of resident CF using the endothelial marker Tie2 (Moore-Morris et al., 2014) which comprise approximately 10% of the left ventricular fibroblasts and have indistinguishable behaviour in response to cardiac injury (Acharya et al., 2012; Tallquist & Molkentin, 2017).

Although activation of myofibroblasts is of central importance in most profibrotic settings, recent evidence—particularly in the setting of metabolic disease, has suggested that increased ECM synthesis may occur in the absence of myofibroblast activation. High glucose-containing media increases collagen production from CF (Zhang et al., 2007; Gu et al., 2017) without myofibroblast activation. Animal studies in diabetic mice have indicated that ECM deposition is upregulated independently of myofibroblast activation and α-SMA expression and is not dependent on TGFβ stimulation (Alex et al., 2018). Furthermore, fibroblasts isolated from the atra of humans with type 2 diabetes have increased expression of collagen I in the absence of TGFβ stimulation (Sedgwick et al., 2014) indicating that CF from diabetic individuals may possess an inherently profibrotic phenotype.

Molecular processes in fibrosis

The molecular processes involved in fibrosis are expansive, complex and interacting, and a comprehensive description is beyond the scope of this review. However, certain groups of factors are frequently implicated in fibrosis and have consequently been explored as potential therapeutic targets. Chief among these is the TGFβ family of proteins, which are potent drivers of fibroblast-to-myofibroblast transition and powerful stimuli for ECM synthesis (Meng et al., 2016).

More recently, a search for factors acting downstream of TGFβ1 led to the re-evaluation of interleukin-11 (IL11) as a profibrotic molecule (Schafer et al., 2017). Similarly, Gal-3 (Shen et al., 2018) and processes resulting in oxidative stress have emerged as new antifibrotic targets (Somanna et al., 2016). A new and alternative paradigm has been to target the fibroblast itself, aiming to deplete myofibroblast populations (Aghajanian et al., 2019). Below, we describe attempts to produce antifibrotic therapies against the more established targets of the TGFβ family and vasoactive peptides before reviewing more novel targeting of IL11, Gal-3, oxidative stress or the activated myofibroblast itself.

Established targets

**TGFβ inhibitors—effective but toxic**

The TGFβ family of proteins are the most well established and potent activators of profibrotic effects in cells, have been implicated in virtually all forms of fibrosis and have been described as the “master regulators” of fibrosis (Meng et al., 2016). TGFβ is a ubiquitously expressed protein with an expansive range of biological effects including enhanced ECM synthesis, cell differentiation, apoptosis, angiogenesis and immune cell function depending on the site of action. Myocardial TGFβ expression is consistently upregulated in the heart of patients with HFrEF irrespective of aetiology including HCM (Li et al., 1997), HHD (Almondur et al., 2010) and aortic stenosis (Hein et al., 2003). There are three isoforms of TGFβ of which TGFβ1 is the most well studied in the context of fibrosis. TGFβ is secreted as an inactive peptide due to the presence of the bound latency-associated peptide (LAP) which prevents it accessing its receptor (Taipale et al., 1994) and is further sequestered into the structure of the ECM by latency TGFβ binding proteins. Dissociation of LAP from TGFβ is an important step in the profibrotic response which occurs in response to tissue damage, inflammation or profibrotic signals and is mediated by a variety of factors which are upregulated in patients with HFrEF. These factors include MMP-2, MMP-9, ADAMTS16 and plasmin which have protease activity that cleaves LAP from the TGFβ molecule (Khalil et al., 1996; Yu & Stamenkovic, 2000; Wang et al., 2006a; Yao et al., 2020). Thrombospondins (Reed et al., 1995), ROS (Barcelos-Hoff & Dix, 1996) and specific integrins (Munger et al., 1999; Wipf et al., 2007) induce a conformational change in the LAP which exposes the receptor binding site on TGFβ molecule. Constitutively, active forms of TGFβ, resistant to LAP inactivation, have been used in both large and small animal models to stimulate atrial and/or ventricular cardiac fibrosis resulting in HF, arrhythmias and reduced survival (Nakajima et al., 2000; Verheule et al., 2004; Accornero et al., 2015; Polejaeva et al., 2016).

Cellular signalling of TGFβ in fibrosis is mediated by the membrane-bound TGFβRII and can involve the canonical, SMAD-dependent pathway or non-canonical, SMAD-independent pathway. In the SMAD-dependent pathway, TGFβ binding induces the formation of a heterotrimeric complex between with TGFβRII and TGFβRII (also known as ALK-5) molecules. Formation of this complex activates the phosphorylation activity of the receptor and activates SMAD2 and SMAD3 (Wells et al., 1999), which dissociate from the receptor and complex with SMAD4 in the cytoplasm (Derynck & Zhang, 2003). This SMAD complex translocates to the nucleus where it binds to SMAD binding elements in the genome to act as a transcription factor independently (Dennler et al., 1998; Martin-Malpartida et al., 2017) or in combination with multiple other transcription factors (Zhang et al., 1998; Mullen et al., 2011). Within the fibroblast, activation of the canonical pathway results in myofibroblast differentiation (Khalil et al., 2017) and upregulation of multiple profibrotic genes including collagen, smooth muscle actin and periostin, along with IL11 (Schafer et al., 2017). Non-canonical signalling mediates similar profibrotic effects in fibroblasts (Chen
et al, 2005; Dolivo et al, 2019), and significant cross-talk exists between these pathways (Engel et al, 1999; Funaba et al, 2002). The mitogen-activated protein kinase (MAPK) pathways—including ERK (Lee et al, 2007), p38 (Molkentin et al, 2017) and JNK (Yoshida et al, 2005)—are chief mediators of this non-canonical response. Blocking this signalling using transgenic mice or specific inhibitors of the MAPK pathways reduces myofibroblast formation and ECM production (Gao et al, 2013; Xu et al, 2017).

TGFβ signalling within the cardiomyocyte also has effects on cardiac remodelling particularly via the non-canonical p38 pathway (Gao et al, 2013; Xu et al, 2017) which influences release of profibrotic mediators in response to stress (Koibata et al, 2011) and upregulates genes related to cardiomyocyte hypertrophy (Matsumoto-Ida et al, 2006). The canonical TGFβ signalling pathway within cardiomyocytes provides important survival signals and maintains contractility during cell stress (Wang et al, 2005; Umbarkar et al, 2019) which may underlie toxicity when inhibiting this pathway.

In vivo, transgenic mice with fibroblast-specific disruption of TGFβR1/2 or SMAD3 protect against cardiac fibrosis and improve diastolic function in response to transverse aortic constriction (TAC) (Khalil et al, 2017). Similarly, mice with a single functional allele of the TGFβ gene are relatively resistant to age-related cardiac fibrosis and have an increased lifespan compared to wild-type mice (Brooks & Conrad, 2000) suggesting a potential therapeutic target. These findings have been replicated in preclinical studies over the last two decades employing either neutralizing monoclonal antibodies (mAb) against TGFβ (Kuwahara et al, 2002; Teekakirikul et al, 2010) or small molecule kinase inhibitors targeting TGFβR1 (Kuwahara et al, 2002; Derangeon et al, 2017) which have markedly reduced cardiac fibrosis and improved LV compliance in rodent models of HFpEF. However, the multifunctional role of TGFβ provides a significant challenge—repeatedly encountered with anti-TGFβ therapy in both animal and human studies—of on-target toxicities that are dose-limiting thus hindering treatment efficacy.

The problems encountered with anti-TGFβ therapies are highlighted in Tgββ1 knockout (KO) mice and humans. Mice have high embryonic lethality and those that survive to birth die between 3 and 5 week of age due to an excessive and widespread inflammatory response resulting in multiorgan failure (Shull et al, 2002; Brilla et al, 1995). AT1R stimulation has also been shown to directly augment the SMAD-arrestin signalling and transactivation of other membrane-bound growth factor receptors. ATIR-mediated β-arrestin signalling (McDonald et al, 2010) and transactivation of PDGFR and epithelial growth factor receptor (EGFR) (Mondorf et al, 2000; Schellings et al, 2006) have all been shown to activate MAPK pathways in CF (Schorb et al, 1995). ATIR stimulation has also been shown to directly augment the SMAD-dependent pathways of TGFβ signalling (Wang et al, 2006b) and in concert with endothelin-1 (ET-1) (Fujisaki et al, 1995) and largely indirectly—induces hypertrophic changes in cardiomyocytes (Gray et al, 1998). In rodents, AngII infusion is a well-established model for stimulating cardiac fibrosis and has been used in many 100s of publications (Sun et al, 1997). This profibrotic effect of AngII is maintained even at subpressor doses which despite not increasing blood pressure results in fibrosis accumulation and diastolic dysfunction (Regan et al, 2015).

In summary, TGFβ signalling is strongly and irreversibly profibrotic in vitro and in vivo and targeting this pathway directly or indirectly has potent antifibrotic effects. However, the toxicity profile associated is consistently too high and is sufficiently dose-limiting to render the treatment ineffective for human disease, to date.

**Renin/angiotensin/aldosterone system inhibitors—mainstay therapy in heart failure**

Targeting the RAAS has been a pillar of HF treatment for over 30 years and is perhaps the seminal success of modern day disease-modifying therapy in HFpEF (Swedberg, 1987; Pfeffer et al, 1992; Pitt et al, 1999). Classically, angiotensin II (AngII) is a profibrotic circulating factor produced by the serial actions of renin- and angiotensin-converting enzymes (ACE) on angiotensinogen. In CF, AngII treatment stimulates myofibroblast formation and ECM production (Brilla et al, 1994; Siddesha et al, 2013). AngII signalling in the heart is mediated through G protein-coupled receptors (GPCR) designated angiotensin receptor type 1 (AT1R) and type 2 (AT2R). The intracellular effect of AngII involves Gq-mediated activation of phospholipase C, β-arrestin signalling and transactivation of other membrane-bound growth factor receptors. ATIR-mediated β-arrestin signalling (McDonald et al, 2000; Rakesh et al, 2010) and transactivation of PDGFR and epithelial growth factor receptor (EGFR) (Mondorf et al, 2000; Schellings et al, 2006) have all been shown to activate MAPK pathways in CF (Schorb et al, 1995). ATIR stimulation has also been shown to directly augment the SMAD-dependent pathways of TGFβ signalling (Wang et al, 2006b) and in concert with endothelin-1 (ET-1) (Fujisaki et al, 1995) and largely indirectly—induces hypertrophic changes in cardiomyocytes (Gray et al, 1998). In rodents, AngII infusion is a well established in vivo model for stimulating cardiac fibrosis and has been used in many 100s of publications (Sun et al, 1997). This profibrotic effect of AngII is maintained even at subpressor doses which despite not increasing blood pressure results in fibrosis accumulation and diastolic dysfunction (Regan et al, 2015).
AT1R antagonists or ACE inhibitors (ACE-I) have in multiple settings reduced ECM production, cardiac hypertrophy and HF in both cell culture and animal models (Pahor et al, 1991; Brilla et al, 1994; Ham et al, 2018). In short-term human studies of HHD, following 6 months of ACE-I treatment the myocardial collagen content on EMB and echocardiographic features of diastolic function were reduced compared to treatment with antihypertensive alone (Brilla et al, 2000). However, multiple clinical trials in HfPEF have failed to demonstrate a mortality benefit or reduction in hospitalization with AnglII inhibition, suggesting that this approach is insufficient to block the activity of the multiple profibrotic pathways which are active in HfPEF and suggests a high degree of redundancy within this system (Yusuf et al, 2003; Cleland et al, 2006; Martin et al, 2018).

Mineralocorticoid receptor antagonists—old drugs but effective
Aldosterone binds to the mineralocorticoid receptor (MR) in the cytoplasm and translocates to the nucleus where it complexes with a variety of co-activators and is responsible for upregulating profibrotic genes. Additionally, aldosterone has multiple non-transcriptional dependent effects which occur more rapidly and can occur independently of the MR (Mihailidou et al, 2004; Markos et al, 2005). In particular, AnglII and aldosterone work synergistically to produce a potent profibrotic effect (Lemarié et al, 2009). Aldosterone augments AnglII signalling by upregulation of MAPK pathways in both cardiomyocytes (Tsai et al, 2013; Somanna et al, 2015) and CF (Stockand & Meszaros, 2003; Lemarié et al, 2009) in a process dependent on G protein-coupled receptor kinases (Cannavo et al, 2016). Aldosterone has been implicated in multiple other processes linked to HfPEF including production of ROS (Hayashi et al, 2008) and development of a pro-inflammatory infiltrate within the heart during pressure overload by promoting differentiation of profibrotic “M2” macrophages (Rickard et al, 2009) and infiltration of profibrotic T cells (Li et al, 2017).

In vivo studies in HfPEF models have been promising with inhibition of this pathway using either cardiomyocyte-specific KO of the MR (Lother et al, 2011; Rickard et al, 2012) or specific MR antagonists (MRA) (Nishiooka et al, 2007; Leader et al, 2019) demonstrating reduced ECM production and improved LV function. Mechanistic studies in humans with MRA have mirrored these results showing a reduction in myocardial collagen accumulation histologically or using ECV on CMR (Table 1; Kosmala et al, 2011; McDiamid et al, 2020).

However—as with ACE-I—rodent and intermediate phenotype studies have so far failed to translate to improved outcomes in large randomized controlled trials (RCT) of MRA in HfPEF (Edelmann et al, 2013; Pitt et al, 2014). A notable caveat is that post hoc analysis of the TOPCAT trial of MRA in HfPEF suggested that hospitalization and symptoms may be improved in subgroups of the population (Giered et al, 2016) and that markers of collagen turnover, PICP and PIINP are reduced (Kosmala et al, 2011; Ravassa et al, 2018; Xiang et al, 2019). Despite this, in the absence of positive prospective RCT data in HfPEF, conclusive evidence for a clinically meaningful cardiac antifibrotic effect of MRA remains elusive.

Neprilysin inhibitors—the “new” old
The natriuretic peptides (NP), atrial natriuretic peptide and brain natriuretic peptide (BNP) are released by cardiomyocytes in response to stress including mechanical stretch or stimulation by profibrotic factors (Li et al, 2003; Pikkarainen et al, 2003). The effects of NP provide endogenous antifibrotic, vasodilatory and natriuretic effects which counters many of the deleterious effects of the RAAS (Kerkela et al, 2015). Natriuretic peptide receptors A (NPRA), B (NPBRB) and C (NPRC) are guanylyl cyclase-coupled receptors, with NPRA being the most relevant in cardiovascular disease (Kerkela et al, 2015). NP binding increases intracellular cGMP and decreases cAMP and IP3 which counters the profibrotic and hypertrophic signalling in fibroblasts and cardiomyocytes (Fujisaki et al, 1995). This protective role is highlighted by the increased fibrosis and LV hypertrophy which occurs animals with KO of BNP gene (Nppb) or NPRA gene (Np1) in response to AnglII infusion or TAC (Tamura et al, 2000; Patel et al, 2005; Parthasarathy et al, 2013).

Exogenous administration of recombinant human BNP has been trialled in patients with acute HF; however, no significant survival or rehospitalization benefit was demonstrated in these trials (O’Connor et al, 2011). The half-life of circulating NPs is under 20 mins as the molecules are readily degraded by the widely expressed membrane-bound peptidase, neprilysin (Charles et al, 1996). Consequently, NPs can be used only as a continuous infusion, unsuitable for use in chronic HF. Inhibitors of the neprilysin peptidase have instead been employed to prolong the half-life of endogenously produced NPs and have shown promise. Treatment with the combination of angiotensin receptor blockers (ARB) and neprilysin inhibitors in diabetic mice results in reduced interstitial fibrosis and cardiomyocyte hypertrophy (Suematsu et al, 2016). Further in vitro experiments have shown that, in contrast to angiotensin receptor inhibition which primarily reduces fibroblast proliferation, the NP system more potently inhibits myofibroblasts activation in response to profibrotic stimuli therefore providing a complimentary antifibrotic effects on the CF (Burke et al, 2019).

Clinical trials of the ARB—neprilysin inhibitor (ARNI) combination of valsartan and sacubitril, have demonstrated significant efficacy in reducing symptoms, hospitalization and mortality in HfPEF in addition to standard therapy, including RAAS inhibition (McMurray et al, 2014). Subgroup analysis showed that an effect on fibrosis may be responsible, in part, for the improvement in outcomes: MMP-2 and MMP-9 levels were lower in treated patients compared to controls, and PINP was also reduced in the treatment group (Zile et al, 2019). However disappointing, a recent RCT in HfPEF failed to meet its primary endpoints of reducing hospitalization for HF or death from cardiovascular causes (Solomon et al, 2019). Exploratory subgroup analysis of this trial has yielded some interesting results in particular a significant improvement in the primary outcome in women (Solomon et al, 2019) which is particularly intriguing given the high burden of HfPEF in women (Vasan et al, 2018), and this finding may stimulate further investigation into sex-specific differences in the development of cardiac fibrosis.

New directions
Given the issues that have emerged with established fibrosis targets, including the lack of clinical benefit in multiple large clinical trials in HfPEF and the toxicities associated with TGFβ therapy, once the front runner, there is a need to identify alternative approaches and targets for fibrosis. This may include augmenting the effects of
Table 1. Clinical trials of drugs where mode of action includes the potential to target cardiac fibrosis that is shown here as an endpoint outcome.

| Treatment                        | Duration | Population | Measure of fibrosis | N Rx vs. placebo | Year    | Fibrosis-related outcome                                      | PMID/NCT       |
|----------------------------------|----------|------------|---------------------|------------------|---------|--------------------------------------------------------------|----------------|
| **Mineralocorticoid receptor antagonists** |          |            |                     |                  |         |                                                              |                |
| Spironolactone                   | 6 months | HFrEF      | PINP/PIIINP         | 81 vs. 70        | 2000    | Reduced PINP/PIIINP                                          | 11094035       |
| Spironolactone                   | 12 months| HFrEF—DCM  | PICP CVF on EMB     | 13 vs. 0         | 2005    | Reduced PICP/CVF                                            | 16275882       |
| Spironolactone                   | 3 months | IHD        | PIIINP              | 98 vs. 98        | 2007    | Reduced PIIINP                                              | 17921831       |
| Eplerenone                       | 6 months | HFrEF      | PINP                | 22 vs. 22        | 2011    | Reduced PINP Improved diastolic function                     | 21807324       |
| Spironolactone                   | 6 months | HFrE—obesity| PICP/PIIINP         | 58 vs. 55        | 2013    | Reduced PIIINP Improved diastolic function                  | 23343682       |
| Spironolactone                   | 6 months | HFrE—female| PIIINP              | 24 vs. 24        | 2014    | Reduced PIIINP Improved diastolic function                  | 24905296       |
| Spironolactone                   | Variable | HFrEF      | PICP                | 167 vs. 161      | 2015    | Reduced PICP Improved diastolic function                     | 26459931       |
| Canrenone                        | 6 months | HFrEF      | PIIINP              | 197 vs. 197      | 2017    | Negative                                                    | 28855452       |
| Spironolactone                   | 12 months| HCM        | PIIINP LGE on CMR   | 26 vs. 27        | 2018    | Negative                                                    | 29604289       |
| Spironolactone                   | 12 months| HFrEF      | PICP                | 190 vs. 180      | 2018    | Reduced PCIP levels Improved diastolic function             | 29709099       |
| Spironolactone                   | 6 months | HFrEF      | ECV on CMR          | 19 vs. 21        | 2019    | Negative                                                    | 31852424       |
| Spironolactone                   | 24 months| HCM        | LGE on CMR          | 130 vs. 130      | Ongoing |                                                             | NCT02948998    |
| **Angiotensin inhibition**       |          |            |                     |                  |         |                                                              |                |
| Lisinopril                       | 6 months | HHD        | CVF on EMB          | 18 vs. 17        | 2000    | Reduced CVF Improved diastolic function                      | 10993857       |
| Losartan                         | 12 months| HHD        | CVF on EMB          | 19 vs. 0         | 2002    | Reduced CVF & improved diastolic function in severe fibrosis | 12034658       |
| Losartan                         | 6 months | HFrE—ESRF  | PICP                | 13 vs. 13        | 2005    | Reduced PICP                                                | 16471172       |
| Enalapril                        | 6 months | HFrE—ESRF  | PICP                | 13 vs. 13        | 2005    | Negative                                                    | 16471172       |
| Irbesartan                       | 12 months| HHD        | PICP                | 56 vs. 58        | 2007    | No difference PICP Improved diastolic function              | 17762662       |
| Irbesartan                       | 6 months | HFrEF      | PIIINP              | 149 vs. 164      | 2011    | Negative                                                    | 21750125       |
| Candesartan                      | 3-4 months| HFrE—Anthracycline| ECV on CMR     | 38 vs. 32        | 2018    | Reduced ECV                                                 | 29106497       |
| Ramipril                         | 36 months| ARVC       | MMP, TIMP           | 60 vs. 60        | Ongoing | –                                                            | 29574980       |
| Valsartan                        | 24 months| HCM        | ECV on CMR          | 75 vs. 75        | Ongoing | –                                                            | 28454798       |
| **Vasodilators**                 |          |            |                     |                  |         |                                                              |                |
| Sildenafil                        | 6 months | HFrEF      | PIIINP              | 113 vs. 103      | 2014    | Negative                                                    | 23478662       |
| Isosorbide dinitrate             | 6 months | HFrEF      | ECV on CMR          | 13 vs. 16        | 2017    | Negative                                                    | 28219917       |
| Isosorbide dinitrate + Hydralazine| 6 months| HFrEF      | ECV on CMR          | 15 vs. 16        | 2017    | Negative                                                    | 28219917       |
| **Neprilysin inhibitors**        |          |            |                     |                  |         |                                                              |                |
| Sacubitril-Valsartan             | 9 months | HFrEF      | PIIINP/MMP2         | 149 vs. 152      | 2016    | Negative                                                    | 26754625       |
currently used treatments, repurposing of drugs which have been proven to be effective in other fibrotic diseases and novel approaches and targets which may provide a much needed alternative antifibrotic treatment.

**Alternative angiotensin inhibitors**

Traditional RAAS inhibition has limited effect in treating cardiac fibrosis in HFrEF; hence, the role of ACE-independent AngII production has been explored as an alternative strategy. Chymases are proteolytic enzymes released predominantly by neutrophils but also by cardiomyocytes and fibroblasts (Urata et al, 1990). Chymases activate angiotensinogen via an alternative pathway independent of ACE bypassing the effect of ACE-I (Prosser et al, 2009; Ahmad et al, 2016; Frouogh et al, 2017). Furthermore, there is evidence that this alternative pathway for AngII production can occur intracellularly without the need for the membrane-bound receptor thereby also evading the action of ARBs (Ferrario et al, 2005; Baker & Kumar, 2006). This *intracellular* pathway may be especially important in diabetes (Singh et al, 2008) and in hypertension where chymase-dependent intracellular AngII synthesis is upregulated (Tadvosyan et al, 2017).

In animal models, chymase inhibitors reduce TGFβ expression, ECM matrix deposition and improve diastolic parameters in the setting of myocarditis or tachycardia-mediated fibrosis (Matsumoto et al, 2003; Palaniyandi et al, 2007; Wei et al, 2010) despite having no significant effect on blood pressure in rodents or humans (Kirimura et al, 2005; Kanefendt et al, 2019). Early clinical trials of oral chymase inhibitors are ongoing, they appear safe in phase I studies (Kanefendt et al, 2019), and this could represent a promising future additive therapy to target the angiotensin pathway.

**Small molecule inhibitors of generic fibrosis pathways**

Treatment of idiopathic pulmonary fibrosis (IPF) has been transformed by the use of the small molecule inhibitors pirfenidone and nintedanib (King et al, 2014; Flaherty et al, 2019), and tranilast has been used in the treatment of asthma and keloid scars for over 30 years in Japan (Darakhshan & Pour, 2015). All three drugs also have antifibrotic effects outside the lung in animals (Seniutkin et al, 2018; Susutlertpanya et al, 2019), and repurposing these drugs for the treatment of cardiac fibrosis is being actively explored.

Pirfenidone and tranilast, through unclear mechanisms (Aimo et al, 2014; Flaherty et al, 2019), and tranilast has...
Pirfenidone and tranilast are already approved for use in humans, and toxicity profiles are well understood. Long-term pirfenidone treatment requires surveillance for hepatotoxicity; however, it is generally well tolerated and tranilast has limited toxicities (Lancaster et al., 2017). The PIROUETTE trial is a clinical study currently ongoing in the UK to investigate the antifibrotic effect of pirfenidone in HFpEF using CMR measures of fibrosis (Lewis et al., 2019). Importantly, this trial is selecting patients with HFpEF based on fibrosis burden using ECV on CMR which will provide a stratified population with proven cardiac fibrosis in contrast to the more heterogeneous populations normally component of HFpEF trials (McMurray & O’Connor, 2014).

Nintedanib, a tyrosine kinase inhibitor, has a wide range of targets including the vascular endothelial growth factor receptor, PDGF and fibroblast growth factor receptor (Hilberg et al., 2008). Its effects on the fibroblast prevent ECM production and myofibroblast activation (Hostettler et al., 2014; Rangarajan et al., 2016). In animal studies of pulmonary hypertension, nintedanib reduces right heart fibrosis and remodelling (Rol et al., 2019). However, studies specifically in HFpEF have yet to be done.

**Galectin-3 inhibitors**

Gal-3 is a member of the lectin family of carbohydrate binding molecules which stimulates ECM production and myofibroblast activation when applied to CF (Shen et al., 2018). The effects of Gal-3 increase macrophages infiltration into the myocardium (Sharma et al., 2004) and increase oxidative stress secondary to the upregulation of NADPH oxidase 4 (NOX4) (He et al., 2017) and downregulation of antioxidant molecules (Ibarrola et al., 2018).

Serum levels of Gal-3 are elevated in HF, and levels are correlated with ventricular dysfunction, arrhythmias and mortality (Ho et al., 2012; Wu et al., 2015). Multiple profibrotic in vivo models increase the expression of Gal-3 in the heart including TAC, AngII or aldosterone infusion (Calvier et al., 2013; Song et al., 2015; Fruenza et al., 2016). The initial work on Gal-3 by Sharma et al. (2004) demonstrated that exogenous infusion of Gal-3 into the pericardial space results in extensive deposition of myocardial collagen and LV dysfunction in rats. Interference with Gal-3 signalling by transgenic KO or specific Gal-3 inhibitors blunts the fibrotic response and prevents LV deterioration in rodent models of pressure overload, hypertension and obesity-related cardiac fibrosis (Yu et al., 2013; Calvier et al., 2015; Martínez-Martínez et al., 2015).

As yet, there have been no clinical trials investigating the effect of Gal-3 inhibitors in HF. However, trials in a number of non-cardiac organ systems are ongoing including pulmonary fibrosis (NCT02257177) non-alcoholic steatohepatitis (NCT02421094) and psoriasis (NCT02407041).

**Oxidative stress**

Oxidative stress is increased in the heart in all forms of HF, and increased ROS is associated with decompensation of HF (Hill & Singal, 1996; Mallat et al., 1998), activation of the MAPK pathways (Tanaka et al., 2001; Qin et al., 2003) and increased interstitial fibrosis (Cheng et al., 2003; Lijnen et al., 2006). Mice with transgenic knockout of the ROS scavenger, superoxide dismutase, rapidly develop cardiac fibrosis and die within 10 days of life (Li et al., 1995). In contrast, overexpression of this enzyme prevents the development of cardiac fibrosis in aged mice (Kwak et al., 2015). The main sources of ROS in HF are derived from mitochondria dysfunction, NADPH oxidases (NOX, particularly NOX2 and 4), nitric oxide synthase and xanthine oxidases (Ide et al., 2000; Morris et al., 2017). Inhibition of the NOX enzymes in particular has emerged as an intriguing antifibrotic target. NOX activity has been found to be upregulated in the explanted hearts of patients with end-stage HF (Heymes et al., 2003; Nediani et al., 2007). Multiple profibrotic factors including AngII (Byrne et al., 2003; Johar et al., 2006), ET-1 (Duerschmidt et al., 2000) and aldosterone (Johar et al., 2006) infusion as well as TAC (Kai et al., 2006; Ago et al., 2010) upregulate the activity of NOX enzymes resulting in increased ROS production in mice.

NOX2 and NOX4 are the major isoforms responsible for ROS production in the heart and are expressed in cardiomyocytes, endothelial cells and fibroblasts (Lassègue et al., 2012; Matsushima et al., 2016). Transgenic global KO of Nox2 reduces cardiac fibrosis in response to AngII or aldosterone infusion compared to wild-type animals (Byrne et al., 2003; Johar et al., 2006). However, NOX2 has an important role in the bactericidal effects of phagocytic cells, and hence, NOX2 deficiency results in granulomatous disease in both mice and humans, making it a challenging therapeutic target (O’Neill et al., 2015).

Nox4 KO mice are phenotypically normal displaying only moderately increased body weight and exhibit no notable immune dysfunction (Carnesecchi et al., 2011). At a cellular level in CF, NOX4 expression is elevated in response to TGFβ signalling (Cucoranu et al., 2005) and knockdown of NOX4 activity using siRNA or small molecule inhibitors reduces fibrosis and myofibroblasts differentiation in response to TGFβ or AngII stimulation (Cucoranu et al., 2005; Chan et al., 2013; Somanna et al., 2016). TAC-mediated myocardial fibrosis is enhanced in mice by transgenic overexpression of Nox4 (Kuroda et al., 2010), and cardiomyocyte-specific KO is protective against myocardial fibrosis and left ventricular dysfunction (Kuroda et al., 2010; Zhao et al., 2015). However, conflicting results have emerged, suggesting that pleiotropic roles of NOX4 in angiogenesis and fatty acid oxidation may be adaptive in the stressed heart and that inhibition of Nox4 may be detrimental in some contexts (Zhang et al., 2010; Nabeebaccus et al., 2017; Schnelle et al., 2019), and it may demonstrate on-target toxicities in other systems, such as promoting atherosclerosis (Schürmann et al., 2015).

Recent translational trials of the NOX1/4 inhibitor GKI37831 in humans were well tolerated in diabetic nephropathy however failed to show a significant reduction in albuminuria at relatively low dose of the drug (Reutens et al., 2019; NCT02101994). Further studies in diabetic nephropathy (Reutens et al., 2019) and idiopathic pulmonary fibrosis (NCT03865927) are planned, and trials of specific NOX inhibitors in cardiac fibrosis may follow depending on the tolerability and success of these trials.

**SGLT2 inhibitors**

SGLT2 inhibitors (SGLT2-I) are a class of antidiabetic drugs that demonstrated unexpectedly beneficial effects in HF during the EMPA-Reg trial in diabetes management (Zinman et al., 2015). This has subsequently been confirmed to be a class effect in alternative SGLT2 inhibitor trials (Neal et al., 2017; McMurray et al., 2019), and much interest has since surrounded the use of these drugs in the management of fibrosis and HFpEF, with or without comorbid diabetes mellitus.
SGLT2 is a membrane transporter acting primarily in the proximal convoluted tubule of the kidney to reabsorb glucose and sodium (Kalra, 2014). Mouse studies demonstrated a reduction in cardiac collagen content and improved indices of diastolic function with SGLT2-I in both diabetic (Habibi et al., 2017; Ye et al., 2017; Li et al., 2019) and non-diabetic animals (Lee et al., 2019; Oh et al., 2019).

However, the mechanism responsible for these cardiovascular effects remains elusive particularly as the SGLT2 receptor is not expressed within the heart (Di Franco et al., 2017). A recent study in mice demonstrated that NOX4 expression was reduced following SGLT2-I treatment with an associated reduction in myocardial oxidative stress (Li et al., 2019) and improvement in both systolic and diastolic function in the diabetic mouse heart (Osorio et al., 2012; Kusaka et al., 2016).

There are also a number of potentially beneficial off-target effects which may play a role in the antifibrotic effects of SGLT2 inhibition. This includes the sodium hydrogen exchanger (Baartscheer et al., 2017) and the SGLT1 channels (Zhou et al., 2003; Di Franco et al., 2017) both of which are expressed within the heart, are involved in myocardial hypertrophy and fibrosis and are targeted by SGLT2-I. A multitude of beneficial systemic effects are also associated with SGLT2-I s including reduction in blood pressure, blood sugar and reduced renal RAAS expression in diabetic mice (Georganos & Agarwal, 2019; Woods et al., 2019), and it is likely that the beneficial effects on cardiac health are multifactorial (Chin et al., 2019).

Clinical studies in HFrEF have demonstrated an improvement in LV mass and diastolic dysfunction following 3 months of SGLT2-I treatment (Verma et al., 2016). However, ECV measured using CMR was not improved after 6 months of SGLT2 inhibition (Hsu et al., 2019). RCTs are currently underway in patients with HFrEF (NCT03619213, NCT03057951), and further mechanistic studies will be vital to improve understanding into the mechanisms involved in these apparent antifibrotic effects.

**Interleukin-11**

IL11 was recently identified as a critical regulator of the TGFβ pathway and cardiac fibrosis: in the absence of IL11 activity, TGFβ cannot exert a profibrotic effect on human cardiac fibroblasts (Schafer et al., 2017). Cell culture experiments with human atrial fibroblasts found that stimulation with TGFβ increases the expression of IL11 mRNA by 8.4-fold on average, making IL11 the most highly upregulated gene downstream of TGFβ/SMAD signalling in CFs. Similar findings have been reported for lung fibroblasts, hepatic stellate cells and coronary artery VSMCs (Lebastchi et al., 2011; Schafer et al., 2017; Ng et al., 2019; Widjaja et al., 2019b).

IL11 is a member of the interleukin-6 (IL6) family of cytokines but has distinct properties from other family members. In the heart, the IL11 receptor (IL11RA1) is highly expressed on fibroblasts (Schafer et al., 2017), and following binding of IL11 to its receptor, it then binds gp130 and results in dimerization of a hexameric receptor complex. Canonical gp130 signalling—crucial for IL6 signalling—occurs via the Jak-STAT pathway and stimulates pro-inflammatory gene transcription. In contrast, IL11 exerts its main effects in human and mouse fibroblasts at the post-transcriptional level, via sustained activation of the non-canonical ERK signalling pathway, with little evidence for a role of STAT although it is mildly phosphorylated (Heinrich et al., 2003; Schafer et al., 2017). In IL11-stimulated fibroblasts, collagen, ACTA2, periostin and MMP2 are strongly upregulated at the protein level but—surprisingly—there is no detectable change in their respective mRNA expression levels. The mechanism underlying this effect is not yet clear, but there is evidence that IL11 stimulates downstream targets of ERK which activate translation, including 40S ribosomal protein S6 kinase and eukaryotic translation initiation factor 4E (Schafer et al., 2017). Glutamyl-prolyl-tRNA synthetase, which mediates translation of proline-rich proteins such as collagen (and IL11 itself), may also play a role in the post-transcriptional control mechanism (preprint: Wu et al., 2019).

In rodents, IL11 is highly expressed in the heart after MI (Obana et al., 2010) or pressure overload (Schafer et al., 2017). In *vivo*, overexpression of IL11 specifically within fibroblasts produces extensive fibrosis across multiple organs including the heart, lungs and kidney along with a HF phenotype (Schafer et al., 2017; Ng et al., 2019). In contrast, mice with germline KO of the mouse *Il11ra1* or following treatment with an IL11 neutralizing mAb exhibit resistance to cardiac fibrosis in response to pressure overload or AngII infusion (Schafer et al., 2017).

These data contrast with previous work that showed recombinant human IL11 (rhIL11) is protective and antifibrotic in the mouse heart (Obana et al., 2010, 2012). However, the use of non-species-specific rhIL11 in these earlier studies is of central importance because more recent work (preprint: Widjaja et al., 2019a) has shown that rhIL11 unexpectedly functions as an inhibitor of endogenous IL11 in mice and rhIL11 does not activate mouse fibroblast ERK signalling (Schafer et al., 2017). In contrast, administration of recombinant mouse IL11 is strongly profibrotic in mice in *vivo* and to mouse fibroblasts in *vitro* (Schafer et al., 2017). In humans, circulating levels of IL11 are elevated in patients with HF, increase with progressive worsening of HF symptoms and are correlated with cardiovascular events including HF hospitalization, stroke, MI and death (Ye et al., 2019).

There is an intriguing side story to IL11, relating to its effect when injected to humans. RhIL11 was developed in the 1990s as a drug (Neumega) for treating chemotherapy-associated thrombocytopenia as it was opportunistically found to increase platelet counts when injected at high doses, although IL11 has no detectable physiological role for normal platelet production (Nandurkar et al., 1997). Notable side effects seen in patients receiving rhIL11 include cardiac arrhythmia including AF, pulmonary congestion, dilutional anaemia and raised brain natriuretic peptide (Smith, 2000; Bhatia et al., 2007; Liu et al., 2019). In a recent study of leukemic patients receiving rhIL11 therapy, all patients exhibited increased BNP levels, 80% reached BNP levels consistent with a diagnosis of HF and 16% developed a clinical HF syndrome (Smith, 2000; Bhatia et al., 2007; Liu et al., 2019).

**Targeting the fibroblast**

As myofibroblasts play a central role in the development of fibrosis, the ability to selectively target-specific populations of fibroblasts is an intriguing potential method to treat fibrotic diseases. The developing oncology treatment, chimeric antigen receptor T-cell (CAR-T cell) therapy, uses re-engineered cytotoxic T cells to target specifically selected surface markers to deplete a defined cell population (June et al., 2018). CAR-T therapy has been used effectively in the clinic to treat B-cell leukaemias and lymphomas resistant to standard therapy by targeting CD19-positive cells (Porter et al., 2011; Schuster et al., 2017; Park et al., 2018). In a recent study, Aghajanian...
et al (2019) repurposed this technology to selectively target fibroblasts. Using RNA sequencing data from the tissue of heart transplant donors and recipients, they identified a surface marker minimally expressed in the normal heart or extracardiac tissue but significantly upregulated in CF of humans with HCM and DCM (Tillmanns et al., 2015; Nagaraju et al., 2019). The marker, fibroblast activation protein (FAP), has previously been shown to be present on activated fibroblasts within malignant tumours (Cortez et al., 2014; Kilvae et al., 2015) and is present in activated CF in mice following AngII/phenylephrine infusion. Selective elimination of FAP-positive cells using this treatment reduced cardiac fibrosis in mice within the 8-week treatment period and improved cardiac function (Aghajanian et al., 2019). Although still at a very early stage of preclinical development, the potential to deplete the activated fibroblast population may be a powerful tool to treat fibrosis within the myocardium and elsewhere.

Another potential method of targeting the CF is to use defined transcription factors to promote fibroblast transdifferentiation towards a cardiomyocyte phenotype, thereby reducing ECM production and potentially augmenting cardiac contraction (Ieda et al., 2010). Delivery of these factors using retroviruses or adeno-associated viral vectors has been trialled successfully in a number of mouse models of HF following MI. Direct injection of the vector into the peri-infarct area induces a significant expression of transcription factors GATA4, MEF2C and Tbx5 within fibroblasts and reprograms these cells towards a cardiomyocyte phenotype (Qian et al., 2012; Song et al., 2012). The result is depletion of the fibroblast population, reduced collagen accumulation and improved cardiac function (Qian et al., 2012; Yoo et al., 2018). This approach remains very much in its infancy and safety concerns remain regarding the use and specificity of viral vectors as well as the arrhythmogenic potential of generating new cardiomyocytes. However, this work again highlights the diversity of the novel tools being explored to treat cardiac fibrosis.

Conclusion

Cardiac fibrosis is central to the pathogenesis of HF, particularly HFP EF, and addressing the lack of available treatments for HFP EF is a priority given the rising demographics of obese, diabetic, hypertensive and ageing populations around the world. The cellular and molecular processes which lead to fibrosis are intricate and overlapping. Some of the pathways and treatment strategies discussed in this review have been understood and used for many decades but none specifically target cardiac fibrosis. It is an exciting time in the field of cardiac fibrosis as several emerging targets and approaches show promise and could be developed to treat, and perhaps even reverse cardiac fibrosis, but this can only be assessed through clinical trials. Given redundancies, it is possible that combination therapies that target multiple components of the fibrotic pathway will be more effective than any single therapy but polypharmacy comes with polytoxicity and this is particularly troublesome in elderly patients. It is important to remember also that HFP EF is a multisystem disorder, and therapies that alleviate skeletal muscle, renal and metabolic dysfunction as well as cardiac dysfunction are likely to have greatest clinical efficacy.

Ultimately, fibrosis depends on activation of the fibroblast and its transformation into a matrix-secreting and pro-inflammatory myofibroblast. This central pathology is a point of convergence for all upstream stimuli: from mechanical stretch to endocrine or paracrine factors. We end by suggesting that targeting non-redundant pathways for myofibroblast activation represents the most promising means of treating fibrosis. While the days of attempting to target TGFβ activation, either directly or indirectly, are likely limited due to dose-limiting, on-target toxicities—new opportunities are available in the form of cell therapy and novel targets, which should be explored.

Conflict of interest

MS and BC have no conflicts of interest to disclose. SAC is a co-inventor on a number of patent applications relating to the role of IL11 in human diseases that include the published patents: WO2017103108, WO2017103108 A2, WO 2018/109174 A2, WO 2018/109170 A2. SAC is also a co-founder, director and shareholder of Enleofen Bio PTE LTD, a Singapore-based biotechnology.

For more information

(i) https://www.escardio.org/Sub-specialty-communities/Heart-Failure-Association-of-the-ESC-(HFA)
(ii) https://www.bsh.org.uk/
(iii) https://www.heart.org/en/health-topics/heart-failure
(iv) https://clinicaltrials.gov

References

Abhayaratna WP, Marwick TH, Smith WT, Becker NG (2006) Characteristics of left ventricular diastolic dysfunction in the community: an echocardiographic survey. Heart 92: 1259 – 1264
Accomaro F, van Berlo JH, Correll RN, Elrod JW, Sargent MA, York A, Rabinowitz JE, Leask A, Molkentin JD (2015) Genetic analysis of connective tissue growth factor as an effector of transforming growth factor β signaling and cardiac remodeling. Mol Cell Biol 35: 2154
Acharya A, Baek ST, Huang G, Eskicioglu B, Goetsch S, Sung CY, Banfi S, Sauer MF, Olsen GS, Duffield JS et al (2012) The BHLH transcription factor Tcf21 is required for lineage-specific EMT of cardiac fibroblast progenitors. Development 139: 2139 – 2149
Aghajanian H, Kimura T, Rurik JG, Hancock AS, Leibowitz MS, Li L, Scholler J, Monslow J, Lo A, Han W et al (2019) Targeting cardiac fibrosis with engineered T cells. Nature 573: 430 – 433

Pending issues

(i) Identify non-redundant mediators of cardiac fibrosis which can be therapeutically targeted with an acceptable safety profile.
(ii) Develop therapies to deplete matrix-secreting cardiac myofibroblasts that do not adversely affect homeostatic functions of resident cardiac fibroblasts.
(iii) Large animal and first-in-man studies for preclinical targets including IL11, gal-3 or NOX inhibition, among others.
(iv) Dissect the interplay of fibrosis and inflammation in the heart to prioritize nodal points of disease pathogenesis and cross-talk.
(v) Identify cross-tissue mediators of fibro-inflammation to enable treatment of the HFP EF, multiorgan syndrome rather than cardiac-specific pathology.
Ago T, Kuroda J, Pain J, Fu C, Li H, Sadoshima J (2010) Upregulation of Nox4 by hypertrophic stimuli promotes apoptosis and mitochondrial dysfunction in cardiac myocytes. Circ Res 106: 1253–1264

Ahmad S, Varagic J, VonCannon JL, Groban L, Collawn JF, Dell’Italia LJ, Ferrario CM (2016) Primacy of cardiac chymase over angiotensin converting enzyme as an angiotensin-(1–12) metabolizing enzyme. Biochem Biophys Res Commun 478: 559–564

Aimo A, Cerbai E, Bartolucci G, Adamo L, Barison A, Lo Surdo G, Giagni S, Passino C, Emdin M (2020) Pirfenidone is a cardioprotective drug: mechanisms of action and preclinical evidence. Pharmacol Res 155: 104694

Alex L, Russo I, Holoborodko V, Frangogiannis NG (2018) Characterization of a mouse model of obesity-related fibrotic cardiomyopathy that recapitulates features of human heart failure with preserved ejection fraction. Am J Physiol Heart Circ Physiol 315: H934 – H949

Almendral JL, Shick V, Rosendorff C, Atlas SA (ª2020) Mark Sweeney et al EMBO Molecular Medicine Bishu K, Hamdani N, Mohammed SF, Kruger M, Ohtani T, Ogut O, Brozovich Bhatia M, Davenport V, Cairo MS (van Amerongen MJ, Bou-Gharios G, Popa ER, van Ark J, Petersen AH, van Dam Anderton MJ, Mellor HR, Bell A, Sadler C, Pass M, Powell S, Steele SJ, Roberts Asgari M, Latifi N, Heis HK, Veli H, Mongeau L (Banerjee I, Fuseler JW, Price RL, Borg TK, Baudino TA (Barcellos-Hoff MH, Dix TA (2006) Intracellular angiotensin II induces cell proliferation independent of AT1 receptor. Am J Physiol Cell Physiol 291: C995 – C1001

Ballal K, Wilson CR, Harmanecy R, Taegtmeyer H (2010) Obesogenic high fat western diet induces oxidative stress and apoptosis in rat heart. Mol Cell Biochem 344: 221 – 230

Banerjee I, Fuseler JW, Price RL, Borg TK, Baudino TA (2007) Determination of cell types and numbers during cardiac development in the neonatal and adult rat and mouse. Am J Physiol Heart Circ Physiol 293: H1883 – H1891

Barcellos-Hoff MH, Dix TA (1996) Redox-mediated activation of latent transforming growth factor-beta 1. Mol Endocrinol 10: 1077 – 1083

Bekfani T, Pellicori P, Morris DA, Ebner N, Valentova M, Steinbeck L, Wachter R, Elsner S, Sliuziuk V, Scheffold JC et al (2016) Sarcopenia in patients with heart failure with preserved ejection fraction: Impact on muscle strength, exercise capacity and quality of life. Int J Cardiol 222: 41 – 46

Bhatia M, Davenport V, Cairo MS (2007) The role of interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with solid tumors, lymphoma, acute myeloid leukemia and bone marrow failure syndromes. Leuk Lymphoma 48: 9 – 15

Bishu K, Hamdani N, Mohammed SF, Kruger M, Ohtani T, Ogut O, Brozovich PV, Burnett JC Jr, Linke WA, Redfield MM (2011) Sildenafil and B-type natriuretic peptide acutely phosphorylate titin and improve diastolic distensibility in vivo. Circulation 124: 2882 – 2891

Boudina S, Sena S, Theobald H, Sheng X, Wright JJ, Hu XX, Aziz S, Johnson JI, Bugger H, Zaha VG et al (2007) Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes 56: 2457 – 2466

Braunwald E (1988) Heart disease: a text book of cardiovascular medicine, 3rd edn. Philadelphia, PA: Elsevier/Saunders

Brennan FR, Cavagnaro J, McKeeer K, Ryan PC, Schutten MM, Vahle J, Weinbauer GF, Marrer-Berger E, Black LE (2018) Safety testing of monoclonal antibodies in non-human primates: case studies highlighting their impact on human risk assessment. MAb 10: 1 – 17

Brilla CG, Zhou G, Matsubara L, Weber KT (1994) Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 26: 809 – 820

Brilla CG, Funkc RC, Rupp H (2000) Lisinopril-mediated regulation of myocardial fibrosis in patients with hypertensive heart disease. Circulation 102: 1388 – 1393

Brooks WW, Conrad CH (2000) Myocardial fibrosis in transforming growth factor beta(1)heterozygous mice. J Mol Cell Cardiol 32: 187 – 195

Brown NJ (2013) Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol 9: 459 – 469

Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert E-M, Nassenstein K, Slosser T, Sabin GV, Sehested U et al (2010) Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 56: 875 – 882

Bui AL, Horwich TB, Fonarow GC (2011) Epidemiology and risk profile of heart failure. Nat Rev Cardiol 8: 30 – 41

Burke RM, Lighthouse JK, Mickelsen DM, Small EM (2019) Sacubitril/valsartan decreases cardiac fibrosis in left ventricle pressure overload by restoring PKG signaling in cardiac fibroblasts. Circ Heart Fail 12: e005655

Byrne JA, Grieve DJ, Bendall JK, Li J-M, Gove C, Lambeth JD, Cave AC, Sham AH (2003) Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin II-induced cardiac hypertrophy. Circ Res 93: 802 – 805

Calderone A, Thaik CM, Takahashi N, Chang DL, Colucci WS (1998) Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 101: 812 – 818

Calvier L, Miana M, Reboul P, Cachofero V, Martinez-Martinez E, de Boer RA, Poirier F, Lacolley P, Zannad F, Rossignon P et al (2013) Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol 33: 67 – 75

Calvier L, Martinez-Martinez E, Miana M, Cachofero V, Rousseau E, Sádaba JR, Zannad F, Rossignon P, López-Andrés N (2013) The impact of Galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. JACC Heart Fail 3: 59 – 67

Cannavo A, Liccardo D, Eguchi A, Elliott KJ, Traynham CJ, Ibetti J, Eguchi S, Byrne JA, Grieve DJ, Bendall JK, Li J-M, Gove C, Lambeth JD, Cave AC, Sham AH (2003) Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin II-induced cardiac hypertrophy. Circ Res 93: 802 – 805

Carnesecchi S, Deffert C, Donati Y, Basset O, Hinz B, Preynat-Seauve O, Guichard C, Arbiser JL, Banfi B, Pache J-C et al (2011) A key role for NOX4 in epithelial cell death during development of lung fibrosis. Antioxid Redox Sign 15: 607 – 619

Chan EC, Peshavariya HM, Liu G-S, Jiang F, Lim S-Y, Dusting CJ (2013) NOX4 modulates collagen production stimulated by transforming growth...
factor β1 in vivo and in vitro. Biochem Biophys Res Commun 430: 918–925

Charles CJ, Espiner EA, Nicholls MG, Richards AM, Yandle TG, Procter A, Kosoglou T (1996) Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep. Am J Physiol 271: R373 – R380

Chen Y, Shi-Wen X, van Beek J, Kennedy L, McLeod M, Renzoni EA, Bou-Charios G, Wilcox-Adelman S, Goetkin PF, Eastwood M et al (2005) Matrix contraction by dermal fibroblasts requires transforming growth factor-beta/activin-linked kinase S, heparan sulfate-containing proteoglycans, and MKK/ERK: insights into pathologic scarring in chronic fibrotic disease. Am J Pathol 167: 1699–1711

Cheng T-H, Cheng P-Y, Shih N-L, Chen I-B, Wang DL, Chen J-J (2008) Involvement of reactive oxygen species in angiotensin II-induced endothelin-1 gene expression in rat cardiac fibroblasts. J Am Coll Cardiol 42: 1845–1854

Chin KL, Ofori-Asenso R, Hopper I, von Lueder TG, Reid CM, Zoungas S, Wang BH, Liew D (2019) Potential mechanisms underlying the cardiovascular benefits of sodium glucose cotransporter 2 inhibitors: a systematic review of data from preclinical studies. Cardiovasc Res 115: 266 – 276

Cho JH, Zhang R, Aynaszyan S, Holm K, Goldhaber JI, Marbán E, Cingolani E (2018) Ventricular arrhythmias underlie sudden death in rats with heart failure and preserved ejection fraction. Circ Arrhythm Electrophysiol 11: e006452

Cleland JC, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J (2006) The perindopril in elderly people with chronic heart failure (PEP–CHF) study. Eur Heart J 27: 2338 – 2345

Cohen JB, Schrauben SJ, Zhao L, Basso MD, Cvijic ME, Li Z, Yarde M, Wang Z, Bhattacharya PT, Chirinos DA (2020) Clinical phenogroups in heart failure with preserved ejection fraction: detailed phenotypes, prognosis, and response to spironolactone. JACC Heart Fail 8: 172 – 184

Collier P, Watson CJ, van Es MH, Phelan D, McCorrigan C, Tolan M, Ledwidge MT, McDonald KM, Baugh JA (2012) Getting to the heart of cardiac remodeling: how collagen subtypes may contribute to phenotype. J Mol Cell Cardiol 52: 148 – 153

Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, Allison M, Hemingway H, Cleland JC, McMurray JJV et al (2018) Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet 391: 572 – 580

Cortez E, Roswall P, Pietras K (2014) Functional subsets of mesenchymal cell types in the tumor microenvironment. Semin Cancer Biol 25: 3 – 9

Cucurullan I, Clempsus R, Dikalova A, Phelann P, Arriyan S, Dikalov S, Sorescu D (2005) NAD(P)H oxidase 4 mediates transforming growth factor-β1–induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 97: 900 – 907

Dai Z, Aoki T, Fukumoto Y, Shimokawa H (2012) Coronary perivascular fibrosis is associated with impairment of coronary blood flow in patients with non-ischemic heart failure. J Cardiol 60: 416 – 421

Darakhshan S, Pour AB (2015) Tranilast: a review of its therapeutic applications. Pharmacol Res 91: 15 – 28

Dennler S, Itch S, Vivien D, ten Dijke P, Huet S, Gauthier JM (1998) Direct binding of Smad3 and Smad4 to critical TGF-beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 17: 3091 – 3100

Derangeon M, Montnach J, Cerpa CO, Jago B, Patin J, Toumaniantz G, Girardeau A, Huang CLH, Collède WH, Grace AA et al (2017) Transforming growth factor β receptor inhibition prevents ventricular fibrosis in a mouse model of progressive cardiac conduction disease. Cardiovasc Res 113: 464 – 474

Derynick R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 425: 577 – 584

Di Carlo SE, Peduto L (2018) The perivascular origin of pathological fibroblasts. J Clin Invest 128: 54 – 63

Di Franco A, Cantini G, Tani A, Coppini R, Zecchi-Orlandini S, Raimondi L, Luconi M, Mannucci E (2017) Sodium-dependent glucose transporters (SGLT) in human ischemic heart: a new potential pharmacological target. Int J Cardiol 243: 86 – 90

Diao K-Y, Yang Z-G, Xu H-Y, Liu X, Zhang Q, Shi K, Jiang L, Xie L-J, Wen L-Y, Guo Y-K (2016) Histologic validation of myocardial fibrosis measured by T1 mapping: a systematic review and meta-analysis. J Cardiovasc Magn Reson 18: 92

Dilez J, Laviades C, Mayor G, Milj J, Monreal I (1995) Increased serum concentrations of procollagen peptides in essential hypertension. Relation to cardiac alterations. Circulation 91: 1450 – 1456

Dilez J, Querejeta R, López B, González A, Larman M, Martínez Ubag JL (2002) Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 105: 2512 – 2517

Dilez J (2004) Profibrotic effects of angiotensin II in the heart. Hypertension 43: 1164 – 1165

Divalakaran V, Adogue J, Ishiyama M, Entman ML, Haudek S, Sivasubramanian N, Mann DL (2009) Adaptive and maladaptive effects of SMAD3 signaling in the adult heart after hemodynamic pressure overloading. Circ Heart Fail 2: 633 – 642

Dolivo DM, Larson SA, Dominko T (2019) Crosstalk between mitogen-activated protein kinase inhibitors and transforming growth factor-β signaling results in variable activation of human dermal fibroblasts. Int J Mol Med 43: 335 – 338

Duca F, Kammerlander Andreas A, Zotte-Tufaro C, Aschauer S, Schweiger Marlene L, Marzflu Beatrice A, Bonderman D, Mascherbauer J (2016) Intersitial fibrosis, functional status, and outcomes in heart failure with preserved ejection fraction. Circ Cardiovasc Imaging 9: e005277

Duerrschmidt N, Wippich N, Goettsch W, Broemme HJ, Morawietz H (2000) Endothelin-1 induces NAD(P)H oxidase in human endothelial cells. Biochem Biophys Res Commun 269: 713 – 717

Dunlay SM, Roger VL, Redfield MM (2017) Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 14: 591 – 602

Echegaray K, Andreu I, Lazkano A, Villanueva I, Saenz A, Elizalde MR, Echegterría V, Lopez B, Carro A, Gonzalez A et al (2017) Role of myocardial collagen in severe aortic stenosis with preserved ejection fraction and symptoms of heart failure. Rev Esp Cardiol 70: 832 – 840

Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, Duvinage A, Stahrenberg K, Löffler M et al (2013) Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the aldol-DHF randomized controlled trial. JAMA 309: 781 – 791

Egberntsen KVT, Skårdal K, Bjørnstad S, Marstein HS, Skrbic B, Sjaastad I, Engebretsen KVT, Skårdal K, Bjørnstad S, Marstein HS, Skrbic B, Sjaastad I, Christensen G, Bjørnstad JL, Tennesen T (2014) Attenuated development of cardiac fibrosis in left ventricular pressure overload by SGL1, an orally active inhibitor of ALK5. J Mol Cell Cardiol 76: 148 – 157

Engel ME, McDonnell MA, Law BK, Moses HL (1999) Interdependent SMAD and JNK signaling in transforming growth factor-beta-mediated transcription. J Biol Chem 274: 37413 – 37420

Eschalier R, Rossignol P, Kearney-Schwartz A, Adamopoulos C, Karatzidou K, Fay R, Mandy D, Marie P-Y, Zannad F (2014) Features of cardiac
remodeling, associated with blood pressure and fibrosis biomarkers, are frequent in subjects with abdominal obesity. Hypertension 63: 740 – 746

Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Cioli D, Quagliaro L, Ceriello A, Giugliano D (2002) Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans. Circulation 106: 2067 – 2072

Everett RJ, Treibel TA, Fukui M, Lee H, Rigoli M, Singh A, Bisterveld P, Tastet L, Musa TA, Dobson L et al (2020) Extracellular myocardial volume in patients with aortic stenosis. J Am Coll Cardiol 75: 304 – 316

Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, Gallagher PE (2005) Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111: 2605 – 2610

Flaherty KR, Wells AJ, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stower S et al (2019) Nintedanib in progressive fibrotic interstitial lung diseases. N Engl J Med 381: 1718 – 1727

Frangogiannis NG (2019) Can myocardial fibrosis be reversed? J Am Coll Cardiol 73: 2283 – 2288

Frantz S, Hu K, Adamek A, Wolf J, Sallam A, Maier SK, Lonning S, Ling H, Ertl L, Musa TA, Dobson L et al (2020) Extracellular myocardial volume in patients with aortic stenosis. J Am Coll Cardiol 75: 304 – 316

Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, Gallagher PE (2005) Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111: 2605 – 2610

Flaherty KR, Wells AJ, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stower S et al (2019) Nintedanib in progressive fibrotic interstitial lung diseases. N Engl J Med 381: 1718 – 1727

Frangogiannis NG (2019) Can myocardial fibrosis be reversed? J Am Coll Cardiol 73: 2283 – 2288

Frantz S, Hu K, Adamek A, Wolf J, Sallam A, Maier SK, Lonning S, Ling H, Ertl L, Bauersachs J (2008) Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction. Basic Res Cardiol 103: 485 – 492

From AM, Maleszewsji J, Rihal CS (2011) Current status of endomyocardial biopsy. Mayo Clin Proc 86: 1095 – 1102

Froogh G, Pinto JT, Le Y, Kandhi S, Alelige M, Huang A, Sun D (2017) Chymase-dependent production of angiotensin II: an old enzyme in old hearts. Am J Physiol Heart Circ Physiol 312: H223 – H231

Frunza O, Russo I, Saxena A, Shinde AV, Humeres C, Hanif W, Rai V, Su Y, Frangogiannis NG (2016) Myocardial Galectin-3 expression is associated with remodeling of the pressure-overloaded heart and may delay the hypertrophic response without affecting survival, dysfunction, and cardiac fibrosis. Am J Pathol 186: 1114 – 1127

Fujisaki H, Ito H, Hirata Y, Tanaka M, Hata M, Lin M, Adachi S, Akimoto H, Marumo F, Hiroe M (1995) Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. J Clin Invest 96: 1059 – 1065

Fukuda N, Wu Y, Nair P, Granzer HL (2005) Phosphorylation of titin modulates passive stiffness of cardiac muscle in a titin isoform-dependent manner. J Gen Physiol 125: 257 – 271

Funaba M, Zimmerman CM, Mathews LS (2002) Modulation of Smad2-mediated signaling by extracellular signal-regulated kinase. J Biol Chem 277: 41361 – 41368

Gao X, Wu G, Gu X, Fu L, Mei C (2013) Kruppel-like factor 15 modulates renal interstitial fibrosis by ERK/MAPK and JNK/MAPK pathways regulation. Kidney Blood Press Res 37: 631 – 640

Georgianos PI, Agarwal R (2019) Ambulatory blood pressure reduction with SGLT2 inhibitors: dose-response meta-analysis and comparative evaluation with low-dose hydrochlorothiazide. Diabetes Care 42: 693 – 700

Girerd N, Ferreira JP, Rossignol P, Zannad F (2016) A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide strain analysis. Eur J Heart Fail 18: 1411 – 1414

Giri SN, Al-Bayati MA, Du X, Schegelie E, Mohr FC, Margolin SB (2004) Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats. Cancer Chemother Pharmacol 53: 141 – 150

González A, Schelbert EB, Diez J, Butler J (2018) Myocardial interstitial fibrosis in heart failure: biological and translational perspectives. J Am Coll Cardiol 71: 1696 – 1706

Gray MO, Long CS, Kalinyak JE, Li HT, Karliner JS (1998) Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts. Cardiovasc Res 40: 352 – 363

Gu X, Fang T, Kang P, Hu J, Yu Y, Li Z, Cheng X, Gao Q (2017) Effect of ALDH2 on high glucose-induced cardiac fibroblast oxidative stress, apoptosis, and fibrosis. Oxid Med Cell Longev 2017: 9257967

Habibi J, Aroor AR, Sowers JR, Jia G, Hayden MR, Garro M, Barron B, Mayoux E, Rector RS, Whaley-Connell A et al (2015) Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol 16: 9

Ham O, Jin W, Lei L, Huang HH, Tsuji K, Huang M, Roh J, Rosenzweig A, Lu HAJ (2018) Pathological cardiac remodeling occurs early in CKD mice from unilateral ureteral obstruction, and is attenuated by Enalapril. Sci Rep 8: 2807

Hara M, Ono K, Kwang M-W, Iwasaki A, Okada M, Nakatani K, Sasayama S, Matsumori A (2002) Evidence for a role of mast cells in the evolution to congestive heart failure. J Exp Med 195: 375 – 381

Hay I, Rich J, Ferber P, Burkhoff D, Maurer MS (2005) Role of impaired myocardial relaxation in the production of elevated left ventricular filling pressure. Am J Physiol Heart Circ Physiol 288: H1203 – H1208

Hayashi H, Kobara M, Abe M, Tanaka N, Couda E, Toba H, Yamada H, Tatsumi T, Nakata T, Matsubara H (2008) Aldosterone nongenomically produces NADPH oxidase-dependent reactive oxygen species and induces myocyte apoptosis. Hypertens Res 31: 363 – 375

He J, Li X, Luo H, Li T, Zhao L, Qi Q, Liu Y, Yu Z (2017) Galectin-3 mediates the pulmonary arterial hypertension-induced right ventricular remodeling through interacting with NADPH oxidase 4. J Am Soc Hypertens 11: 275 – 289.e2

Hein S, Arnon E, Kostin S, Schönburg M, Elsasser A, Polyakova V, Bauer EP, Klövekorn W-P, Schaper J (2003) Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 107: 984 – 991

Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374: 1 – 20

Heymes C, Bendall JK, Ratajczak P, Cave AC, Samuel J-L, Hasenfuss G, Shah AM (2003) Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 41: 2164 – 2171

Hilberg F, Roth GJ, Kassak M, Kautschitsch S, Sommergruber W, Tontsch-Grunz U, Garn-Chesa P, Bader G, Zoephel A, Quant J et al (2008) BBF 1120: triple angio kinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 68: 4774 – 4782

Hill MF, Singhal PK (1996) Antioxidant and oxidative stress changes during heart failure subsequent to myocardial infarction in rats. Am J Pathol 148: 291 – 300

Hinglais N, Heudes D, Nicoletti A, Mandet C, Laurent M, Bariéty J, Michel JB, Maumus P, Sun Q, Mandal J, Lardinois D, Lambers C et al (2014) Anti-fibrotic
effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. *Respir Res* 15: 157

Hsu JC, Wang CY, Su MM, Lin LY, Yang WS (2019) Effect of emapagliflozin on cardiac function, adiposity, and diffuse fibrosis in patients with type 2 diabetes mellitus. *Sci Rep* 9: 15348

Hudon-David F, Bouzeghrane F, Couture P, Thibault G (2007) Thy-1 expression by cardiac fibroblasts: lack of association with myofibroblast contractile markers. *J Mol Cell Cardiol* 42: 991–1000

Hummel YM, Liu LCY, Lam CSM, Fonseca-Munoz DF, Damman K, Rienstra M, van der Meer P, Rosenkranz S, van Veldhuisen DJ, Voors AA et al (2017) Echocardiographic estimation of left ventricular and pulmonary pressures in patients with heart failure and preserved ejection fraction: a study utilizing simultaneous echocardiography and invasive measurements. *Eur J Heart Fail* 19: 1651–1660

Ibarrola J, Arrieta V, Sádaba R, Martinez-Martinez E, Garcia-Peña A, Alvarez V, Fernández-Celis A, Gainsa A, Santamaría E, Fernández-Ingiyen J et al (2018) Galectin-3 down-regulates antioxidant peroxiredoxin-4 in human cardiac fibroblasts: a new pathway to induce cardiac damage. *Clin Sci* 132: 1471–1485

Ide T, Tsutsui H, Kinugawa S, Suematsu N, Hayashidani S, Ichikawa K, Utsumi H, Machida Y, Egashira K, Takeshita A (2000) Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium. *Circ Res* 86: 152–157

Ieda M, Fu J-D, Delgado-Olguin P, Vedantham V, Hayashi Y, Bruneau BG, Srivastava D (2010) Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 142: 375–386

Ivey MJ, Tallquist MD (2016) Defining the cardiac fibroblast. *Circ J* 80: 2269–2276

Johar S, Cave AC, Narayananapicker A, Grieve DJ, Shah AM (2006) Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. *FASEB J* 20: 1546–1548

June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC (2018) CAR T cell immunotherapy for human cancer. Science 359: 1361–1365

Kai H, Mori T, Tokuda K, Takayama N, Tahara N, Takeshita K, Kudo H, Sugiy S, Fukui D, Yasukawa H et al (2006) Pressure overload-induced transient oxidative stress mediates perivascular inflammation and cardiac fibrosis through angiotensin II. *Hypertens Res* 29: 711–718

Kalra S (2014) Sodium Glucos Co-Transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology. *Diabetes Ther* 5: 355–366

Kanagala P, Cheng ASH, Singh A, Khan JN, Gulsin GS, Patel P, Gupta P, Arnold JR, Squire IB, Ng LL et al (2019) Relationship between focal and diffuse fibrosis assessed by CMR and clinical outcomes in heart failure with preserved ejection fraction. *JACC Cardiovasc Imaging* 12: 2291–2301

Kanefendt F, Thuss U, Becka M, Boxnick S, Berse M, Schultz A, Otto C (2019) Pharmacokinetics, safety, and tolerability of the novel chymase inhibitor BAY 1142524 in healthy male volunteers. *Clin Pharmacol Drug Dev* 8: 467–479

Kanisicak O, Khalil H, Ivey MJ, Karch J, Maliken BD, Correll RN, Brody MJ, Sc JL, Aronow BJ, Tallquist MD et al (2016) Genetic lineage tracing defines myofibroblast origin and function in the injured heart. *Nat Commun* 7: 12260

Kasner M, Westermann D, Lopez B, Gaub R, Escher F, Kühl U, Schultheiss H-P, Tschöpe C (2011) Diastolic tissue doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction. *J Am Coll Cardiol* 57: 977

Kelly JP, Mentz RJ, Mebazaa A, Voors AA, Butler J, Roessig L, Fiuzaat M, Zannad F, Pitt B, O'Connor CM et al (2015) Patient selection in heart failure with preserved ejection fraction clinical trials. *J Am Coll Cardiol* 65: 1668–1682

Kerkela R, Ulvila J, Magga J (2015) Natriuretic peptides in the regulation of cardiovascular physiology and metabolic events. *Am Heart Assoc* 4: e002423

Khalil N, Corne S, Whitman C, Yacyszyn H (1996) Plasmin regulates the activation of cell-associated latent TGF-beta 1 secreted by rat alveolar macrophages after *in vivo* bleomycin injury. *Am J Respir Cell Mol Biol* 15: 252–259

Khalil H, Kanisicak O, Prasad V, Correll RN, Fu X, Schips T, Vagnozzi RJ, Liu R, Huynh T, Lee S-J et al (2017) Fibroblast-specific TGF-β-Smad2/3 signaling underlies cardiac fibrosis. *J Clin Invest* 127: 3770–3783

Klauser TK, Khanekhani MR, Hellevik T, Al-Saad S, Paulsen E-E, Bremnes RM, Busund L-T, Donnem T, Martinez IZ (2015) Cancer associated fibroblasts in stage I-IIA NSCLC: prognostic impact and their correlations with tumor molecular markers. *PloS ONE* 10: e0134965

Kim GR, Uziel N, Burkhoff D (2018) Reverse remodelling and myocardial recovery in heart failure. *Nat Rev Cardiol* 15: 83–96

King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L et al (2014) A Phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. *N Engl J Med* 370: 2083–2092

Kirimura K, Takai S, Jin D, Muramatsu M, Kishi K, Yoshikawa K, Nakabayashi M, Mino Y, Miyazaki M (2005) Role of chymase-dependent angiostatin II formation in regulating blood pressure in spontaneously hypertensive rats. *Hypertens Res* 28: 457–464

Kobayashi H, Kobayashi Y, Yokoe I, Akashi Y, Takei M, Giles JT (2017) Magnetic resonance imaging-detected myocardial inflammation and fibrosis in rheumatoid arthritis: associations with disease characteristics and N-terminal pro-brain natriuretic peptide levels. *Arthritis Care Res* 69: 1304–1311

Koibataki N, Danner T, Zaiman AL, Pinto YM, Rowell J, Mankowski J, Zhang K, Tobe K, Kadowaki T (2011) Pivotal role of cardiac fibrosis of TGF-β signaling in the murine pathological response to sustained pressure overload. *J Clin Invest* 121: 2301–2312

Kojima M, Shiojima I, Yamazaki T, Komuro I, Zou Z, Wang Y, Mizuno T, Ueki K, Tobe K, Kadowaki T (1994) Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in *in vivo* and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro. *Circulation* 89: 2204–2211

Kong P, Christia P, Saxena A, Yu S, Frangogiannis NG (2013) Lack of specificity of fibroblast-specific protein 1 in cardiac remodeling and fibrosis. *Am J Physiol Heart Circ Physiol* 305: H1363–H1372

Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, Mysiak A, O’Moore-Sullivan T, Marwick TH (2011) A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome. *JACC Cardiovasc Imaging* 4: 1239–1249

Kosmala W, Marwick TH (2020) Asymptomatic left ventricular diastolic dysfunction: predicting progression to symptomatic heart failure. *JACC Cardiovasc Imaging* 13: 215–227

Kotlarz D, Marquardt B, Baray T, Lee WS, Konnikova L, Holliceck S, Magg T, Lehle AS, Walz C, Borggraebe I et al (2018) Human TGF-β1 deficiency causes severe inflammatory bowel disease and encephalopathy. *Nat Genet* 50: 344–348

Kovacs RJ, Maldonado G, Azaro A, Fernández MS, Romero FL, Sepulveda-Sánchez JM, Corretti M, Carducci M, Dolan M, Gueorguieva I et al (2015) Cardiac safety of TGF-β1 receptor I kinase inhibitor LY2157299 monohydrate in cancer patients in a first-in-human dose study. *Cardiovasc Toxicol* 15: 309–323
Kraigher-Krainer E, Shah AM, Gupta DK, Santos A, Claggett B, Pieske B, Zile MR, Voors AA, Lefkowitz MP, Packer M et al (2014) Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. J Am Coll Cardiol 63: 447 – 456

Kramann R, Schneider RK, DiRocco DP, Machado F, Fleig S, Bondzio PA, Henderson JM, Ebert BL, Humphreys BD (2015) Perivascular G\(\text{G}13\) + progenitors are key contributors to injury-induced organ fibrosis. Cell Stem Cell 16: 51 – 66

Krenning G, Zeisberg EM, Kalluri R (2010) The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol 225: 631 – 637

Krittayaphong R, Boonyasirinant T, Chaithiraphan V, Maneesai A, Kusaka H, Koibuchi N, Hasegawa Y, Ogawa H, Kim-Mitsuyama S (2016) The role of T-box transcription factors in the mechanism of cardiac fibrosis. Cell Stem Cell 18: 225 – 238

Kwak H-B, Lee Y, Kim J-H, Van Remmen H, Richardson AG, Lawler JM (2013) Impact of mitochondrial dysfunction on aging mouse heart. J Gerontol A Biol Sci Med Sci 68: 118 – 126

Kwong RY, Sattar H, Wu H, Vorobiof G, Gandla V, Steel K, Siu S, Brown KA Lacouture ME, Morris JC, Lawrence DP, Tan AR, Olencki TE, Shapiro GI, Dezuwe B, Bertozzyla HS, Fu J, Guitart J (2015) Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor \(\beta\) by the monoclonal antibody foresilimumab (GC1008). Cancer Immunol Immunother 64: 437 – 446

Lancaster LH, de Andrade JA, Zibjak J, Padilla ML, Albera C, Nathan SD, Wijsenbeek MS, Stauffer JL, Kirchgaessler K-U, Costabel U (2017) Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. Eur Respir Rev 26: 170057

Lassègue B, San Martín A, Griendling KK (2012) Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system. Circ Res 110: 1364 – 1390

Leader CJ, Moharram M, Coffey S, Sammut IA, Wilkins GW, Walker RJ (2019) Myocardial global longitudinal strain: an early indicator of cardiac intrastitial fibrosis modified by spironolactone, in a unique hypertensive rat model. PloS ONE 14: e0220837

Lebastchi AH, Qin L, Khan SF, Zhou J, Geirsson A, Kim RW, Li W, Tellides G (2011) Activation of human vascular cells decreases their expression of transforming growth factor-beta. Atherosclerosis 219: 417 – 424

Lee MK, Pardoux C, Hall MC, Lee PS, Warburton D, Qing J, Smith SM, Derynck R (2007) TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of Shc. EMBO J 26: 3957 – 3967

Lee H-C, Shiou Y-L, Juho S-J, Chang C-Y, Liu P-L, Jhuang W-J, Dai Z-K, Chen W-Y, Chen Y-F, Lee A-S (2019) The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats. Cardiiosc Diabetol 18: 45

Lemarié CA, Simeone SMC, Nikonova A, Ebrahimian T, Deschênes M-E, Coffman TM, Paradis P, Schiffin EL (2009) Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors. Circ Res 105: 852 – 859

Lesyk W, Kriza C, Kolominsky-Rabas P (2018) Cost-of-illness studies in heart failure: a systematic review 2004–2016. BMC Cardiovasc Disord 18: 74

Lewis GA, Schelbert EH, Naish JH, Redson E, Dodd S, Eccleson H, Clayton D, Jimenez BD, McDonagh T, Williams SG et al (2019) Pirfenidone in heart failure with preserved ejection fraction: rationale and design of the PIROUETTE trial. Cardiiosc Drugs Ther 33: 461 – 470

Li Y, Huang TT, Carlson EJ, Melov S, Urssel PC, Olson JL, Noble LJ, Yoshimura MP, Berger C, Chan PH et al (1995) Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat Genet 11: 376 – 381

Li RK, Li G, Mickle DA, Weisel RD, Merante F, Luss H, Rao V, Christakis GT, Williams WG (1997) Overexpression of transforming growth factor-beta1 and insulin-like growth factor-i in patients with idiopathic hypertrophic cardiomyopathy. Circulation 96: 874 – 881

Li C, Sun X-N, Zeng M-R, Zheng X-J, Zhang Y-Y, Wan Q, Zhang W-C, Shi C, Du L-J, Ai T-J et al (2017) Mineralocorticoid receptor deficiency in T cells attenuates pressure overload-induced cardiac hypertrophy and dysfunction through modulating T-cell activation. Hypertension 70: 137 – 147

Li C, Zhang J, Xue M, Li X, Han F, Liu X, Xu L, Yu Y, Cheng Y, Li T et al (2019) SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiiosc Diabetol 18: 15

Liang F, Gardner DG (1999) Mechanical strain activates BNP gene transcription through a p38/ERK-kappaB-dependent mechanism. J Clin Invest 104: 1603 – 1612

Lijnen P, Papparella I, Petrov V, Semplicini A, Faggard R (2006) Angiotensin II-stimulated collagen production in cardiac fibroblasts is mediated by reactive oxygen species. J Hypertens 24: 757 – 766

Liu J, Masurekar MR, Vatner DE, Jyothirmayi GN, Regan TJ, Vatner SF, Meggs LG, Malhotra A (2003) Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart. Am J Physiol Heart Circ Physiol 285: H2587 – H2591

Liu N-W, Huang X, Liu S, Liu W-J, Wang H, Wang W, Lu Y (2019) Elevated BNP caused by recombinant human interleukin-11 treatment in patients...
with chemotherapy-induced thrombocytopenia. Support Care Cancer 27: 4293–4298
Löffler AI, Pan JA, Balfour PC Jr, Shaw PW, Yang Y, Nasir M, Auger DA, Epstein FH, Kramer CM, Gan L-M et al (2019) Frequency of coronary microvascular dysfunction and diffuse myocardial fibrosis (measured by cardiovascular magnetic resonance) in patients with heart failure and preserved left ventricular ejection fraction. Am J Cardiol 124: 1584–1589
Lombardi R, Betocchi S, Losi MA, Tocchetti CG, Aversa M, Miranda M, D’Alessandro G, Cacace A, Ciampi Q, Chiarucci M (2003) Myocardial collagen turnover in hypertrophic cardiomyopathy. Circulation 108: 1455–1460
López B, González A, Querejeta R, Larman M, Díez J (2006) Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol 48: 89–96
López B, González A, Querejeta R, Larman M, Díez J (2014) Association of cardiophrin-1 with myocardial fibrosis in hypertensive patients with heart failure. Hypertension 63: 483–489
López B, González A, Querejeta R, Zubillaga E, Larman M, Díez J (2015a) Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin. Eur J Heart Fail 17: 385–392
López B, González A, Ravassa S, Beaumont J, Moreno MU, San José G, Querejeta R, Díez J (2015b) Circulating biomarkers of myocardial fibrosis: the need for a reappraisal. J Am Coll Cardiol 65: 2449–2456
López B, Ravassa S, González A, Zubillaga E, Bonavila C, Bergés M, Echeagaray K, Beaumont J, Moreno MU, San José G et al (2016) Myocardial collagen cross-linking is associated with heart failure hospitalization in patients with hypertensive heart failure. J Am Coll Cardiol 67: 251
Lother A, Berger S, Gilbsch R, Rösner S, Ecke A, Barreto F, Bauersachs J, Schütz G, Hein L (2011) Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function. Hypertension 57: 746–754
Mailat Z, Philip I, Lebret M, Chatel D, Maclouf J, Tedgui A (1998) Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation 97: 1536–1539
Markos F, Healy V, Harvey BJ (2005) Aldosterone rapidly activates Naf/H+ exchange in M-1 cortical collecting duct cells via a PKC-MAPK pathway. Nephron Physiol 99: 1–9
Martin J, Kelly DJ, Mifsud SA, Zhang Y, Cox AJ, See F, Krum H, Wilkinson-Berka J, Gilbert RE (2005) Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-beta. Cardiovasc Res 65: 694–701
Martin N, Manoharan K, Thomas J, Davies C, Lumbers RT (2018) Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Cochrane Database Syst Rev 6: CD012721
Martinez-Martinez E, López-Ándres N, Jurado-López R, Rousseau E, Bartolomé Marín V, Fernández-Celis A, Rossignol P, Islas F, Antequera A, Prieto S et al (2015) Galectin-3 participates in cardiovascular remodeling associated with obesity. Hypertension 66: 961–969
Martin-Malpartida P, Batet M, Kaczmarska Z, Freier R, Gomes T, Aragón E, Zou Y, Wang Q, Xu Q, Ruiz L et al (2017) Structural basis for genome wide recognition of 5-bp GC motifs by SMAD transcription factors. Nat Commun 8: 2070
Martos R, Baugh J, Ledwidge M, O’Loughlin C, Murphy NF, Conlon C, Patie A, Donnelly SC, McDonald K (2009) Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover. Eur J Heart Fail 11: 191–197
Mascherbauer J, Marzluff BA, Tufaro C, Paffenberger S, Graf A, Wexberg P, Panzenbock A, Jakowitsch J, Bangert C, Laimer D et al (2013) Cardiac magnetic resonance postcontrast T1 time is associated with outcome in patients with heart failure and preserved ejection fraction. Circ Cardiovasc Imaging 6: 1056–1065
Matsumoto T, Wada A, Tsutamoto T, Ohnishi M, Isono T, Kinoshita M (2003) Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure. Circulation 107: 2555–2558
Matsumoto-Ida M, Takimoto Y, Aoyama T, Akao M, Takeda T, Kita T (2006) Activation of TGF-β1-TAK1-p38 MAPK pathway in spared cardiomyocytes is involved in left ventricular remodeling after myocardial infarction in rats. Am J Physiol Heart Circ Physiol 290: H709–H715
Matsushima S, Kinugawa S, Sadoshima J, Tsutsui H (2016) NADPH oxidase 4 is a major source of mitochondrial reactive oxygen species in the heart. J Card Fail 22: S159
McDiarmid AK, Swoboda PP, Erhayem B, Bounfour KA, Bisterveld P, Tyndall K, Fent Gj, Garg P, Dobson LE, Musa TA et al (2020) Myocardial effects of aldosterone antagonism in heart failure with preserved ejection fraction. J Am Heart Assoc 9: e011521
McDonald PH, Chow CW, Miller WE, Laporte SA, Field ME, Lin FT, Davis RJ, Lefkowitz RJ (2000) Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. Science 290: 1574–1577
McMurray JVF, O’Connor C (2014) Lessons from the TOPCAT Trial. N Engl J Med 370: 1453–1454
McMurray JVF, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Roqueu JL, Shi VC, Solomon SD, Swedberg K et al (2014) Angiotensin-nephrilysin inhibition versus enalapril in heart failure. N Engl J Med 371: 993–1004
McMurray JVF, Solomon SD, Inzucchi SE, Kaber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Böhmilová J et al (2019) Dagapiliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381: 1995–2008
Meng X-M, Nikolic-Paterson DJ, Lan HY (2016) TGF-β: the master regulator of fibrosis. Nat Rev Nephrol 12: 325–338
Mihailidou AS, Mardini M, Funder JW (2004) Rapid, nongenomic effects of aldosterone in the heart mediated by epsilon protein kinase C. Endocrinology 145: 773–780
Mitra MS, Lancaster K, Adedeji AO, Palanisamy GS, Dave RA, Zhong F, Holdren MH, Turley SJ, Liang W-C, Wu Y et al (2020) A potent Pan-TGFβ neutralizing monoclonal antibody elicits cardiovascular toxicity in mice and cynomolgus monkeys. Toxicol Sci 175: 24–34
Molkentin JD, Bugg D, Ghearing N, Dorn LE, Kim P, Sargent MA, Gunaye J, Otsu K, Davis J (2017) Fibroblast-specific genetic manipulation of p58 mitogen-activated protein kinase in vivo reveals its central regulatory role in fibrosis. Circulation 136: 549–561
Mondorf UF, Geiger H, Herrero M, Zeuzem S, Piiper A (2013) Chymase inhibition versus enalapril in heart failure. J Am Coll Cardiol 61: 1584–1589
Moravsky G, Ofek E, Rakowski H, Butany J, Williams L, Ralph-Edwards A, Wintersberger BJ, Crean A (2013) Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR. JACC Cardiovasc Imaging 6: 587–596
Moreo A, Ambrosio G, De Chiara B, Pu M, Tran T, Mauri F, Raman SV (2009) Influence of myocardial fibrosis on left ventricular diastolic function. Circ Cardiovasc Imaging 2: 437 – 443

Moris D, Spatarris M, Tzatzaki E, Spatarris E, Karachalios G-S, Triantafyllis AS, Karaloanis GI, Tsilimigris DI, Theocharis S (2017) The role of reactive oxygen species in myocardial redox signaling and regulation. Ann Transl Med 5: 324

Mullen AC, Orlando DA, Newman Jj, Lovén J, Kumar RM, Bildeau S, Reddy J, Guenther MC, DeKoter RP, Young RA (2011) Master transcription factors determine cell-type-specific responses to TGF-β signaling. Cell 147: 565 – 576

Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SJ, Wu J, Pittet JF, Kaminski N, Carat C, Mattthy MA et al (1999) The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96: 319 – 328

Nabbeaccus AA, Zoccarato A, Hafstad AD, Santos CX, Aasum E, Brewer AC, Zhang M, Beretta M, Yin X, West JA et al (2017) Nox4 reprograms cardiac substrate metabolism via protein O-GlcNAcylation to enhance stress adaptation. JCI Insight 2: e96184

Nagao K, Inada T, Tamura A, Kajitani K, Shimamara K, Yukawa H, Aida K, Sowa N, Nishiga M, Horie T et al (2018) Circulating markers of collagen types I, III, and IV in patients with dilated cardiomyopathy: relationships with myocardial collagen expression. ESC Heart Fail 5: 1044 – 1051

Nagaraju CJ, Robinson EL, Adesesseem M, Trenson S, Dries E, Gilbert G, Konnens S, Van Cleeempt J, Rega F, Meyns B et al (2019) Myofibroblast phenotype and reversibility of fibrosis in patients with end-stage heart failure. J Am Coll Cardiol 75: 2267 – 2282

Nakajima H, Nakajima HO, Salcher O, Dembowsky K, Jing S, Field LJ, Nagaraju CK, Robinson EL, Abdesselem M, Trenson S, Dries E, Gilbert G, Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, Pittet JF, Nakatani Y, Nishida K, Sakabe M, Kataoka N, Sakamoto T, Yamaguchi Y, Komuro I, Takeda K, Matsumiya G et al (2010) Therapeutic activation of signal transducer and activator of transcription 3 by interleukin-11 ameliorates cardiac fibrosis after myocardial infarction. Circulation 121: 684 – 691

Obana M, Maeda M, Takeda K, Hayama A, Mohri T, Yamashita T, Nakaoka Y, Komuro I, Takeda K, Matsumiya G et al (2010) Suppression of atrial natriuretic peptide/natriuretic peptide receptor-A-mediated signaling upregulates angiotensin-II-induced hypertensive mouse: involvement of tenasin-C induced by aldosterone-mediated inflammation. J Cardiovasc Pharmacol 49: 261 – 268

Norton GR, Tsotetsi J, Trifunovic B, Hartford C, Candy GP, Woodiwiss AJ (1997) Myocardial stiffness is attributed to alterations in cross-linked collagen rather than total collagen or phenotypes in spontaneously hypertensive rats. Circulation 96: 1991 – 1998

Obana M, Miyamoto K, Murasawa S, Iwakura T, Hayama A, Yamashita T, Shiragaki M, Kumagai S, Miyawaki A, Takekawa K et al (2012) Therapeutic administration of IL-11 exhibits the postconditioning effects against ischemia-reperfusion injury via STAT3 in the heart. Am J Physiol Heart Circ Physiol 303: H569 – H577

O’Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JVF et al (2011) Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 365: 32 – 43

Oh CM, Cho S, Jang JY, Kim H, Chun S, Choi M, Park S, Ko YG (2019) Cardioprotective potential of an SGLT2 inhibitor against doxorubicin-induced heart failure. Korean Circ J 49: 1183 – 1195

Okayama K, Azuma J, Dosaka N, Iekushi K, Sanada F, Kusunoki H, Iwabayashi M, Rakugi H, Taniyama Y, Morishita R (2012) Hepatocyte growth factor reduces cardiac fibrosis by inhibiting endothelial-mesenchymal transition. Hypertension 59: 958 – 965

Okoshi MP, Yan X, Okoshi K, Nakayama M, Schultd AJT, O’Connell TD, Simpson PC, Lorell BH (2004) Aldosterone directly stimulates cardiac myocyte hypertrophy. J Card Fail 10: 511 – 518

O’Neill S, Braut J, Stasia M-J, Knus A (2015) Genetic disorders coupled to ROS deficiency. Redox Biol 6: 135 – 156

Osorio H, Coronel I, Arellano A, Pacheco U, Pacheco R, Franco M, Escalante B (2013) Master transcription factors: a mechanism for regulating endothelial-mesenchymal transition. Hypertension 59: 958 – 965

Palaniyandi SS, Nagai Y, Watanabe K, Ma M, Veeraveedu PT, Prakash P, Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JVF et al (2011) Suppression of atrial natriuretic peptide/natriuretic peptide receptor-A-mediated signaling upregulates angiotensin-II-induced hypertensive mouse: involvement of tenasin-C induced by aldosterone-mediated inflammation. J Cardiovasc Pharmacol 49: 261 – 268

Paulin J, Valencik ML, Pritchett AM, Burnett JC, McDonald JA, Redfield MM (2005) Cardiac-specific attenuation of natriuretic peptide A receptor disease: correlation with quantitative histopathology. Am Heart J 157: 361 – 368

Nishioka T, Suzuki M, Onishi K, Takakura N, Inada H, Yoshida T, Hiroe M, Imanaka-Yoshida K (2007) Eplerenone attenuates myocardial fibrosis in the angiotensin II-induced hypertensive mouse: involvement of tenasin-C induced by aldosterone-mediated inflammation. J Cardiovasc Pharmacol 49: 261 – 268

Norton GR, Tsotetsi J, Trifunovic B, Hartford C, Candy GP, Woodiwiss AJ (1997) Myocardial stiffness is attributed to alterations in cross-linked collagen rather than total collagen or phenotypes in spontaneously hypertensive rats. Circulation 96: 1991 – 1998

Obana M, Maeda M, Takeda K, Hayama A, Mohri T, Yamashita T, Nakaoka Y, Komuro I, Takeda K, Matsumiya G et al (2010) Therapeutic activation of signal transducer and activator of transcription 3 by interleukin-11 ameliorates cardiac fibrosis after myocardial infarction. Circulation 121: 684 – 691

Obana M, Miyamoto K, Murasawa S, Iwakura T, Hayama A, Yamashita T, Shiragaki M, Kumagai S, Miyawaki A, Takekawa K et al (2012) Therapeutic administration of IL-11 exhibits the postconditioning effects against ischemia-reperfusion injury via STAT3 in the heart. Am J Physiol Heart Circ Physiol 303: H569 – H577

O’Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JVF et al (2011) Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 365: 32 – 43

Oh CM, Cho S, Jang JY, Kim H, Chun S, Choi M, Park S, Ko YG (2019) Cardioprotective potential of an SGLT2 inhibitor against doxorubicin-induced heart failure. Korean Circ J 49: 1183 – 1195

Okayama K, Azuma J, Dosaka N, Iekushi K, Sanada F, Kusunoki H, Iwabayashi M, Rakugi H, Taniyama Y, Morishita R (2012) Hepatocyte growth factor reduces cardiac fibrosis by inhibiting endothelial-mesenchymal transition. Hypertension 59: 958 – 965

Okoshi MP, Yan X, Okoshi K, Nakayama M, Schultd AJT, O’Connell TD, Simpson PC, Lorell BH (2004) Aldosterone directly stimulates cardiac myocyte hypertrophy. J Card Fail 10: 511 – 518

O’Neill S, Braut J, Stasia M-J, Knus A (2015) Genetic disorders coupled to ROS deficiency. Redox Biol 6: 135 – 156

Osorio H, Coronel I, Arellano A, Pacheco U, Bautista R, Franco M, Escalante B (2012) Sodium-glucose cotransporter inhibition prevents oxidative stress in the kidney of diabetic rats. Oxd Med Cell Longev 2012: 542042

Pahor M, Bernabei R, Sgadari A, Gambassi G Jr, Lo Giudice P, Pacifici L, Ramacci MT, Lagrasta C, Olivetti G, Carbonin P (1991) Enalapril prevents cardiac fibrosis and arrhythmias in hypertensive rats. Hypertension 18: 148 – 157

Palaniyandi SS, Nagai Y, Watanabe K, Ma M, Veeraveedu PT, Prakash P, Kamal FA, Abe Y, Yamaguchi K, Tachikawa H et al (2007) Chymase inhibition reduces the progression to heart failure after autoimmune myocarditis in rats. Exp Biol Med 232: 1213 – 1221

Park JH, Riviere I, Gonen M, Wang X, Sénéchal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E et al (2018) Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 378: 449 – 459

Parthasarathy A, Gopi V, Umadevi S, Simma A, Sheikh M, Divya H, Veilachamy E (2013) Suppression of atrial natriuretic peptide/natriuretic peptide receptor-A-mediated signaling upregulates angiotensin-II-induced collagen synthesis in adult cardiac fibroblasts. Mol Cell Biochem 378: 217 – 228

Patel JB, Valencik ML, Pritchett AM, Burnett JC, McDonald JA, Redfield MM (2005) Cardiac-specific attenuation of natriuretic peptide A receptor
activity accentuates adverse cardiac remodeling and mortality in response to pressure overload. Am J Physiol Heart Circ Physiol 289: H777—H784

Paulus WJ, Tschöpe C (2013) A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62: 263—271

Peet C, Ivicevic A, Bromage DJ, Shah AM (2019) Cardiac monocytes and macrophages after myocardial infarction. Cardiovasc Res 116: 1101—1112

Pfeffer MA, Shah AM, Borlaug BA (2009) Heart failure with preserved ejection fraction in perspective. Circ Res 124: 1598—1617

Picchi A, Gao X, Belmadani S, Potter BJ, Focardi M, Chilian WM, Zhang C (2006) Tumor necrosis factor-alpha induces endothelial dysfunction in the prediabetic metabolic syndrome. J Biol Chem 281: 11189—11197

Pinto AR, Ilinykh A, Ivey MJ, Kubwaba JT, D’Antoni ML, Debuque R, Chandran A, Wang L, Arora K, Rosenthal NA et al (2016) Revisiting cardiac cellular composition. Circ Res 118: 400—409

Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Picchi A, Gao X, Belmadani S, Potter BJ, Focardi M, Chilian WM, Zhang C (2000) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 342: 669—677

Pfeffer MA, Shah AM, Borlaug BA (2019) Heart failure with preserved ejection fraction in perspective. Circ Res 124: 1598—1617

Picchi A, Gao X, Belmadani S, Potter BJ, Focardi M, Chilian WM, Zhang C (2006) Tumor necrosis factor-alpha induces endothelial dysfunction in the prediabetic metabolic syndrome. J Biol Chem 281: 11189—11197

Pinto AR, Ilinykh A, Ivey MJ, Kubwaba JT, D’Antoni ML, Debuque R, Chandran A, Wang L, Arora K, Rosenthal NA et al (2016) Revisiting cardiac cellular composition. Circ Res 118: 400—409

Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341: 709—717

Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL et al (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370: 1383—1392

Polajeva IA, Ranjan R, Davies CJ, Regoussi M, Hall J, Olsen AL, Meng Q, Rutziglino HM, Dosdall DJ, Angel NA et al (2016) Increased susceptibility to atrial fibrillation secondary to atrial fibrosis in transgenic goats expressing transforming growth factor-β1. J Cardiovasc Electrophysiol 27: 1220—1229

Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, Jaarsma T, Krum H, Rastogi V, Rohde LE et al (2014) Heart failure: preventing disease and death worldwide. ESC Heart Fail 1: 4—25

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Creagh J, Hauer J, Jankowska EA et al (2016) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37: 2129—2200

Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365: 725—733

Prosser HCC, Forster ME, Richards AM, Pemberton CJ (2009) Cardiac chymases convert rat proAngiotensin-12 (PA12) to angiotensin II: effects of PA12 upon cardiac haemodynamics. Cardiovasc Res 82: 40—50

Qian L, Huang Y, Spencer CJ, Foley A, Vedantham V, Liu L, Conway SJ, Fu J-D, Srivastava D (2012) In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature 485: 593—598

Qin F, Shite J, Liang C-S (2003) Antioxidants attenuate myocyte apoptosis and improve cardiac function in CHF: association with changes in MAPK pathways. Am J Physiol Heart Circ Physiol 285: H822—H832

Querejeta R, Varo N, López B, Larman M, Artiñano E, Etayo JC, Ubago JL, Gutierrez-Stampa M, Empanza JG, Gil MJ et al (2000) Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 101: 1729—1735

Querejeta R, López B, González A, Sánchez E, Larman M, Martínez Ubago JL, Díez J (2004) Increased collagen type I synthesis in patients with heart failure of hypertensive origin. Circulation 110: 1263—1268

Rakesh K, Yoo B, Kim I-M, Salazar N, Kim K-S, Rockman HA (2010) beta-Arrestin-biased agonism of the angiotensin receptor induced by mechanical stress. Sci Signal 3: ra46

Ranganarajan S, Kurundkar A, Kurundkar D, Bernard K, Sanders YY, Ding Q, Antony VB, Zhang J, Zmijewski J, Thannickal VJ (2016) Novel mechanisms for the antifibrotic action of nintedanib. Am J Respir Cell Mol Biol 54: 51—59

Ravassa S, Trippel T, Bach D, Bachran D, González A, López B, Wachter R, Hasenfuss G, Delles C, Dominiczak AF et al (2018) Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial. Eur J Heart Fail 20: 1290—1299

Reed MJ, Iruela-Arispe L, O’Brien ER, Truong T, LaBelle T, Bornstein P, Sage EH (1995) Expression of thrombospondins by endothelial cells. Injury is correlated with TSP-1. Am J Pathol 147: 1068—1080

Regan JA, Mauro AG, Carbone S, Marchetti C, Gill R, Mezzaroma E, Valle Raleigh J, Salloum FN, Van Tassell BW, Abbate A et al (2015) A mouse model of heart failure with preserved ejection fraction due to chronic infusion of a low subpressor dose of angiotensin II. Nature 529: 270—277

Reutens AT, Jandelet-Dahm K, Thomas M, Bach LA, Colman PG, Davis TME, Emsden M, Ekinci EI, Fulcher G, Hamblin PS et al (2019) A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: protocol and statistical considerations. Contemp Clin Trials 90: 105892

Rice LM, Padilla CM, McLaughlin SR, Mathes A, Ziemek J, Goummih S, Nakerakanti S, York M, Farina G, Whitfield ML et al (2015) Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J Clin Invest 125: 2795—2807

Rickard AJ, Morgan J, Tesch G, Funder JW, Fuller PJ, Young MJ (2009) Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 54: 537—543

Rickard AJ, Morgan J, Bienvenue LA, Fletcher EC, Cranston GA, Shen JZ, Reichelt ME, Delbridge LM, Young MJ (2012) Cardiomyocyte mineralocorticoid receptors are essential for deoxycorticosterone/salt-mediated inflammation and cardiac fibrosis. Hypertension 60: 1443—1450

Rockey DC, Bell PD, Hill JA (2015) Fibrosis—a common pathway to organ injury and failure. N Engl J Med 372: 1138—1149

Rol N, de Raaf MA, Sun XQ, Kuiper VP, da SilvaConcalvesRos D, Happe C, Kurakula K, Dickhoff C, Thuijlet R, Tu L et al (2019) Nintedanib improves cardiac fibrosis but leaves pulmonary vascular remodelling unaltered in experimental pulmonary hypertension. Cardiovasc Res 115: 432—439

Rommel K-P, von Roeder M, Latus cynski K, Oberueck C, Blakez S, Fengler K, Besler C, Sandri M, Lücke C, Gutberlet M et al (2016) Extracellular volume...
fraction for characterization of patients with heart failure and preserved ejection fraction. *J Am Coll Cardiol* 67: 1815 – 1825

Rosenblum J, Macarak E, Piera-Velazquez S, Jimenez SA (2017) Human fibrotic diseases: current challenges in fibrosis research. *Methods Mol Biol* 1627: 1 – 23

Rudolph A, Abdel-Aty H, Bohl S, Boyé P, Zagrosek A, Dietz R, Schulz-Menger J (2009) Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy related to remodeling. *J Am Coll Cardiol* 53: 284 – 291

Santini V, Valcárcel D, Platzecker U, Komroki RS, Clevery LA, Lahn MM, Janssen J, Zhao Y, Chiang A, Giagounidis A et al (2019) Phase II study of the ALK inhibitor galunisertib in very low-, low-, and intermediate-risk myelodysplastic syndromes. *Clin Cancer Res* 25: 6976 – 6985

Schafer S, Viswanathan S, Widjaja AA, Lim W-W, Moreno-Moral A, Delaughter DM, Ng B, Patone G, Chow K, Khin E et al (2017) IL-11 is a crucial determinant of cardiovascular fibrosis. *Nature* 552: 110 – 115

Schelbert EB, Hsu Y-L, Anderson SA, Mohanty BD, Karim SM, Kellman P, Schafer S, Viswanathan S, Widjaja AA, Lim W-W, Moreno-Moral A, Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, Brogdon JL, Sedgwick B, Riches K, Bageghni SA, Orsborn I, Schorb W, Conrad KM, Singer HA, Dostal DE, Baker KM (2018) Effects of pirfenidone in acute and chronic diabetes. *J Clin Pathol* 46: 32 – 36

Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D (1992) Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. *Nature* 359: 693 – 699

Siddhesha JM, Valente AJ, Sakamuri SSV, Yoshida T, Gardner JD, Somanna N, Takahashi C, Noda M, Chandrasekar B (2013) Angiotensin II stimulates cardiac fibroblast migration via the differential regulation of matrixins and RECK. *J Mol Cell Cardiol* 65: 9 – 18

Singh VP, Le B, Khode R, Baker KM, Kumar R (2008) Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. *Diabetes* 57: 3297 – 3306

Smith JW II (2000) Tolerance and side-effect profile of rhIL-11. *Oncology* 14: 41 – 47

Smith CL, Baek ST, Sung CY, Tallquist MD (2011) Epicardial-derived cell epithelioid-to-mesenchymal transition and fate specification require PDGF receptor signaling. *Circ Res* 108: e15 – e26

Solomon SD, McMurray J, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B et al (2019) Angiotensin- nepilysin inhibition in heart failure with preserved ejection fraction. *N Engl J Med* 381: 1609 – 1620

Somanna NK, Yarinswamy M, Garaglione JM, Siebenlist U, Mummidi S, Valente AJ, Chandrasekar B (2015) Aldosterone-induced cardiomyocyte growth, and fibroblast migration and proliferation are mediated by TRAF3IP2. *Cell Signal* 27: 1928 – 1938

Somanna NK, Valente AJ, Krenz M, Fay WP, Delaunay P, Chandrasekar B (2016) The Nox1/4 dual inhibitor CTKT137831 or Nox4 knockdown inhibits angiotensin-II-induced adult mouse cardiac fibroblast proliferation and migration. AT1 physically associates with Nox4. *J Cell Physiol* 231: 1130 – 1141

Song K, Nam Y-J, Luo X, Qi X, Tan W, Huang GN, Acharya A, Smith CL, Tallquist MD, Neilson EG et al (2012) Heart repair by reprogramming non-myocytes with cardiac transcription factors. *Nature* 485: 599 – 604

Song X, Qian X, Shen M, Jiang R, Wagner MB, Ding G, Chen G, Shen B (2013) Protein kinase C promotes cardiac fibrosis and heart failure by modulating Galectin-3 expression. *Biochim Biophys Acta* 1853: 513 – 521

Sorop O, Heinonen I, van Kranenburg M, van de Wouw J, de Beer VJ, Nguyen ITN, Octavia Y, van Duin RWB, Stam K, van Geuns R et al (2018) Multiple common comorbidities produce left ventricular diastolic dysfunction associated with coronary microvascular dysfunction, oxidative stress, and myocardial stiffening. *Cardiovasc Res* 114: 954 – 964

d’Souza RR (2002) Aging of myocardial collagen. *Biogerontology* 3: 325 – 335

Stauber AJ, Credille KM, Triux LL, Ehihardt WJ, Young JK (2014) Nonclinical safety evaluation of a transforming growth factor β Receptor I kinase inhibitor in fischer 344 rats and beagle dogs. *J Clin Toxicol* 4: 3
Treibel TA, López B, González A, Menacho K, Schofield RS, Ravassa S, Fontana M, White SK, DiSalvo C, Roberts N et al (2018a) Reappraising myocardial fibrosis in severe aortic stenosis: an invasive and non-invasive study in 133 patients. Eur Heart J 39: 699 – 709
Treibel TA, Kozor R, Schofield R, Benedetti G, Fontana M, Bhuva AN, Sheik A, López B, González A, Manisty C et al (2018b) Reverse myocardial remodeling following valve replacement in patients with aortic stenosis. J Am Coll Cardiol 71: 860 – 871
Tsa C-F, Yang S-F, Chu H-J, Ueng K-C (2013) Cross-talk between mineralocorticoid receptor/angiogenin II type 1 receptor and mitogen-activated protein kinase pathways underlies aldosterone-induced atrial fibrotic responses in HL-1 cardiomyocytes. J Int Cardiol 169: 17 – 28
Turner NA, Mughal RS, Warburton P, O'Regan DJ, Ball SG, Porter KE (2007) Mechanism of TNFalpha-induced IL-1alpha, IL-1beta and IL-6 expression in human cardiac fibroblasts: effects of statins and thiazolidinediones. Cardiovasc Res 76: 81 – 90
Umare V, Pradhan V, Nadkar M, Rajadhyaksha A, Patwardhan M, Ghosh KK, Nadkarni AH (2014) Effect of proinflammatory cytokines (IL-6, TNF-alpha, and IL-1beta) on clinical manifestations in Indian SLE patients. Mediators Inflamm 2014: 385297
Umbarkar P, Singh AP, Gupta M, Verma VK, Galindo CL, Guo Y, Zhang Q, McNamara JW, Force T, Lal H (2019) Cardiomyocyte SMAD4-dependent TGF-beta signaling is essential to maintain adult heart homeostasis. JACC Basic Trans Sci 4: 41
Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A (1990) Identification of a highly specific chymase as the major angiogenin II-forming enzyme in the human heart. J Biol Chem 265: 22348 – 22357
Vasan RS, Xanthakis V, Lyass A, Andersson C, Tsao C, Cheng S, Aragam J, Benjamin EJ, Larson MG (2018) Epidemiology of left ventricular systolic dysfunction and heart failure in the Framingham Study. JACC Cardiovasc Imaging 11: 1
Veheulle S, Sato T, Everett T IV, Engle SK, Otten D, Rubart-von der Lohe M, Nakajima HO, Nakajima H, Field LJ, Olgin JE (2004) Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ Res 94: 1458 – 1465
Verma S, Garg A, Yan AT, Gupta AK, Al-Omran M, Sabongui A, Teoh H, Mazer CD, Connelly KA et al (2016) Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG outcome trial? Diabetes Care 39: e212
Villari B, Vassalli G, Monrad ES, Chiariello M, Turina M, Hess OM (1999) Normalization of diastolic dysfunction in aortic stenosis late after valve replacement. Circulation 99: 2353 – 2358
Vincenti F, Fervenza FC, Campbell KN, Diaz M, Gesualdo L, Nelson P, Praga M, Radhakrishnan J, Sellin L, Singh A et al (2017) A phase 2, double-blind, placebo-controlled, randomized study of fresolimumab in patients with steroid-resistant primary focal segmental glomerulosclerosis. Kidney Int Rep 2: 800 – 810
Vitiello D, Harel F, Touyz RM, Siros MG, Lavie J, Myers J, Ducharme A, Racine N, O'Meara E, Gayda M et al (2014) Changes in cardiopulmonary reserve and peripheral arterial function concomitantly with subclinical inflammation and oxidative stress in patients with heart failure with preserved ejection fraction. Int J Vasc Med 2014: 917271
Voelker J, Berg PH, Sheetz M, Duffin K, Shen T, Moser B, Greene T, Blumenthal RS, Rychlik I, Yagil Y et al (2017) Anti-TGF-beta1 antibody therapy in patients with diabetic nephropathy. J Am Soc Nephrol 28: 953 – 962
Waddingham MT, Sonobe T, Tsuchimochi H, Edgley AJ, Sukumaran V, Chen YC, Hansra SS, Schwenke DO, Umetani K, Aoyama K et al (2019) Diastolic dysfunction is initiated by cardiomyocyte impairment ahead of
endothelial dysfunction due to increased oxidative stress and inflammation in an experimental prediabetes model. J Mol Cell Cardiol 137: 119–131

Walther T, Schubert A, Falk V, Binner C, Kanev A, Bleiziffer S, Walther C, Doll N, Autschbach R, Mohr FW (2001) Regression of left ventricular hypertrophy after surgical therapy for aortic stenosis is associated with changes in extracellular matrix gene expression. Circulation 104: I54–I58

Wang J, Xu N, Feng X, Hou N, Zhang J, Cheng X, Chen Y, Zhang Y, Yang X (2005) Targeted disruption of Smad4 in cardiomyocytes results in cardiac hypertrophy and heart failure. Circ Res 97: 821–828

Wang M, Zhao D, Spinetti G, Zhang J, Jiang L-Q, Pintus G, Monticone R, Lakatta EG (2006a) Matrix metalloproteinase 2 activation of transforming growth factor-beta1 (TGF-beta1) and TGF-beta1-type II receptor signaling within the aged arterial wall. Arterioscler Thromb Vasc Biol 26: 1503–1509

Wang W, Huang XR, Canlas E, Oka K, Truong LD, Deng C, Bhowmick NA, Ju W, Bottinger EP, Lan HY (2006b) Essential role of Smad3 in angiotensin II-induced vascular fibrosis. Circ Res 98: 1032–1039

Wang Y, Wu Y, Chen J, Zhao S, Li H (2013) Pirfenidone attenuates cardiac fibrosis in a mouse model of TAC-induced left ventricular remodeling by suppressing NLRP3 inflammasome formation. Cardiovasc Diabetol 126: 1–11

Weber KT (1989) Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol 13: 1637–1652

Wei CC, Hase N, Inoue Y, Bradley EW, Yahiro E, Li M, Naqvi N, Powell PC, Shin K, Takahashi Y et al (2010) Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents. J Clin Invest 120: 1229–1239

Wells RG, Gilboa L, Sun Y, Liu X, Henis Y, Lodish HF (1999) Transforming growth factor-beta induces formation of a dithiothreitol-resistant type I/Type II receptor complex in live cells. J Biol Chem 274: 5716–5722

Westermann D, Kasner M, Steendijk P, Spellmann F, Riad A, Westmann K, Hoffmann W, Poller W, Pauschinger M, Schultheiss H-P (2011) Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail 4: 44–52

Whittaker P, Kloer BP, Bougner DR, Pickering JG (1994) Quantitative assessment of myocardial collagen with picrosirius red staining and circularly polarized light. Basic Res Cardiol 89: 397–410

Widijaja AA, Dong J, Adami E, Viswanathan S, Ng B, Singh BK, Lim WW, Zhou J, Pakkiri LS, Shekeran SG et al (2019a) Redefining interleukin 11 as a regenerating-limiting hepatotxin. bioRxiv https://doi.org/10.1101/830018 [PREPRINT]

Widijaya AA, Singh BK, Adami E, Viswanathan S, Dong J, D’Agostino GA, Ng B, Lim WW, Tan J, Paleja BS et al (2019b) Inhibiting interleukin 11 signaling reduces hepatocyte death and liver fibrosis, inflammation, and steatosis in mouse models of non-alcoholic steatohepatitis. Gastroenterology 157: 777–792

Widyantoro B, Emoto N, Nakayama K, Anggrahini Dyah W, Adiarto S, Iwasa N, Yagi K, Miyagawa K, Rikitate Y, Suzuki T et al (2010) Endothelial cell-derived endothelin-1 promotes cardiac fibrosis in diabetic hearts through stimulation of endothelin-to-mesenchymal transition. Circulation 121: 2407–2418

Wipff P-J, Rifkin DB, Meister J-J, Hinz B (2007) Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix. J Cell Biol 179: 1311–1323

Woods TC, Satou R, Miyata K, Katsurada A, Dugas CM, Klingenberg NC, Fonseca VA, Navar LG (2019) Canagliflozin prevents intrarenal angiotensinogen augmentation and mitigates kidney injury and hypertension in mouse model of type 2 diabetes mellitus. Am J Nephrol 49: 331–342

Wu C-K, Su M-Y, Lee J-K, Chiang F-T, Hwang J-J, Lin J-L, Chen J-J, Liu F-T, Tsai C-T (2015) Galectin-3 level and the severity of cardiac diastolic dysfunction using cellular and animal models and clinical indices. Sci Rep 5: 17007

Wu J, Subbiah KCV, Xie LH, Jiang F, Mickelsen D (2019) EPRS regulates proline-rich pro-fibrotic protein synthesis during cardiac fibrosis. bioRxiv https://doi.org/10.1101/77490 [PREPRINT]

Wynn TA (2008) Cellular and molecular mechanisms of fibrosis. J Pathol 214: 199–210

Xiang Y, Shi W, Li Z, Yang Z, Wang SY, Xiang R, Feng P, Wen L, Huang W (2019) Efficacy and safety of spironolactone in the heart failure with mid-range ejection fraction and heart failure with preserved ejection fraction: a meta-analysis of randomized clinical trials. Medicine 98: e14967

Xu Y, Xiao H, Luo H, Chen Y, Zhang Y, Tao L, Jiang J, Chen Y, Shen X (2017) Inhibitory effects of oxymatrine on TGF-β1-induced proliferation and abnormal differentiation in rat cardiac fibroblasts via the p38MAPK and ERK1/2 signaling pathways. Mol Med Rep 16: 5354–5362

Yamazaki T, Yamashita N, Izumi Y, Nakamura Y, Shiota M, Hanatani A, Shimada K, Muro T, Iwao H, Yoshiyama M (2012) The anti-fibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice. Hypertens Res 35: 34–40

Yang JH, Obokata M, Reddy YNV, Redfield MM, Lerman A, Boriaug BA (2020) Endothelium-dependent and independent coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. Eur J Heart Fail 22: 432–441

Yao Y, Hu C, Song Q, Li Y, Da X, Yu Y, Li H, Clark IM, Chen Q, Wang QK (2020) ADAMTS16 activates latent TGF-β, accentuating fibrosis and dysfunction of the pressure-overloaded heart. Circ Res 116: 956–969

Ye Y, Bajaj M, Yang HC, Perez-Polo JR, Birnbaum Y (2017) SGLT2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor. Cardiovasc Drugs Ther 31: 119–132

Ye J, Wang Z, Ye D, Wang Y, Wang M, Ji Q, Huang Y, Liu L, Shi Y, Shi L et al (2019) Increased interleukin-11 levels are correlated with cardiac events in patients with chronic heart failure. Mediators Inflamm 2019: 8

Yoo SY, Jeong S-N, Kang J-I, Lee S-W (2018) Chimeric adeno-associated virus-mediated cardiovascular reprogramming for ischemic heart disease. ACS Omega 3: 5918–5925

Yoshida K, Matsuokz K, Mni S, Tahashi Y, Yamagata H, Furukawa F, Seki T, Nishizawa M, Fujisawa J, Okazaki K (2005) Transforming growth factor-beta, and platelet-derived growth factor signal via c-Jun N-terminal kinase-dependent Smad2/3 phosphorylation in rat hepatic stellate cells after acute liver injury. Am J Pathol 166: 1029–1039

Yu Q, Stamenkovic I (2000) Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14: 163–176

Yu X, Deng L, Wang D, Li N, Chen X, Cheng X, Yuan J, Gao X, Liao M, Wang M et al (2012) Mechanism of TNF-α autocrine effects in hypoxic cardiomyocytes: initiated by hypoxia inducible factor 1α, presented by exosomes. J Mol Cell Cardiol 53: 848–857

Yu L, Ruffrok Willem PT, Meissner M, Bos Eelke M, van Goor H, Sanjabi B, van der Harst P, Pitt B, Goldstein Irwin J, Koerts Jasper A et al (2013) Genetic
and pharmacological inhibition of Galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail 6: 107–117

Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362: 777 – 781

Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, Chandraker A, Yuan X, Pu WT, Roberts AB et al (2007) Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 13: 952 – 961

Zhang Y, Feng XH, Derynck R (1998) Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced transcription. Nature 394: 909 – 913

Zhang X, Stewart JA Jr, Kane ID, Massey EP, Cashatt DO, Carver WE (2007) Effects of elevated glucose levels on interactions of cardiac fibroblasts with the extracellular matrix. In Vitro Cell Dev Biol Anim 43: 297 – 305

Zhang M, Brewer AC, Schröder K, Santos CXC, Grieve DJ, Wang M, Anilkumar N, Yu B, Dong X, Walker SJ et al (2010) NADPH oxidase-4 mediates protection against chronic load-induced stress in mouse hearts by enhancing angiogenesis. Proc Natl Acad Sci USA 107: 18121 – 18126

Zhao QD, Viswanadhapalli S, Williams P, Shi Q, Tan C, Yi X, Bhandari B, Abboud HE (2015) NADPH oxidase 4 induces cardiac fibrosis and hypertrophy through activating Akt/mTOR and NFκB signaling pathways. Circulation 131: 643 – 655

Zhou L, Cryan EV, D’Andrea MR, Belkowski S, Conway BR, Demarest KT (2003) Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1). J Cell Biochem 90: 339 – 346

Zile MR, Baicu CF, Gaasch WH (2004) Diastolic heart failure–abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 350: 1953 – 1959

Zile MR, Baicu CF, Ikonomidis JS, Stroud RE, Nierst PJ, Bradshaw AD, Slater R, Palmer BM, Van Buren P, Meyer M et al (2013) Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation 131: 1247 – 1259

Zile MR, O’Meara E, Claggett B, Prescott MF, Solomon SD, Swedberg K, Packer M, McMurray JJV, Shi V, Lefkowitz M et al (2019) Effects of sacubitril/valsartan on biomarkers of extracellular matrix regulation in patients with HFrEF. J Am Coll Cardiol 73: 795 – 806

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ et al (2015) Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 373: 2117 – 2128

License: This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.